---
document_datetime: 2023-09-21 19:00:16
document_pages: 62
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/lympreva-epar-public-assessment-report_en.pdf
document_name: lympreva-epar-public-assessment-report_en.pdf
version: success
processing_time: 79.8496642
conversion_datetime: 2025-12-28 05:04:55.204274
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 April 2015 EMA/314727/2015 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Lympreva

International non-proprietary name: dasiprotimut-t

## Procedure No. EMEA/H/C/002772/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                               | ..............................................6                                                           |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier                                                                                           | .....................................................................................6                    |
| 1.2. Manufacturers                                                                                                       | .....................................................................................................7    |
| 1.3. Steps taken for the assessment of the product                                                                       | ........................................................7                                                 |
| 2. Scientific discussion                                                                                                 | ................................................................................8                         |
| 2.1. Introduction                                                                                                        | ........................................................................................................8 |
| 2.2. Quality aspects..................................................................................................   | 10                                                                                                        |
| 2.2.1. Introduction ...................................................................................................  | 10                                                                                                        |
| 2.2.2. Active Substance.............................................................................................     | 10                                                                                                        |
| 2.2.3. Finished Medicinal Product................................................................................        | 14                                                                                                        |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects                                                     | ............................. 16                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                | ...................... 17                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................                     | 18                                                                                                        |
| 2.3. Non-clinical aspects............................................................................................    | 18                                                                                                        |
| 2.3.1. Introduction                                                                                                      | ................................................................................................... 18    |
| 2.3.2. Pharmacology.................................................................................................     | 18                                                                                                        |
| 2.3.3. Pharmacokinetics                                                                                                  | ............................................................................................ 22           |
| 2.3.4. Ecotoxicity/environmental risk assessment.........................................................                | 22                                                                                                        |
| 2.3.5. Discussion on non-clinical aspects .....................................................................          | 22                                                                                                        |
| 2.4. Conclusion on the non-clinical aspects                                                                              | .................................................................. 23                                     |
| 2.5. Clinical aspects..................................................................................................  | 23                                                                                                        |
| 2.5.1. Introduction ...................................................................................................  | 23                                                                                                        |
| 2.5.2. Pharmacokinetics                                                                                                  | ............................................................................................ 24           |
| 2.5.4. Discussion on clinical pharmacology ..................................................................            | 26                                                                                                        |
| 2.5.5. Conclusions on clinical pharmacology.................................................................             | 26                                                                                                        |
| 2.6. Clinical efficacy.................................................................................................. | 26                                                                                                        |
| 2.6.1. Dose response studies .....................................................................................       | 26                                                                                                        |
| 2.6.2. Main study                                                                                                        | ..................................................................................................... 26  |
| 2.6.3. Discussion on clinical efficacy............................................................................       | 45                                                                                                        |
| 2.6.4. Conclusions on the clinical efficacy ....................................................................         | 46                                                                                                        |
| 2.7. Clinical safety                                                                                                     | .................................................................................................... 46   |
| 2.7.1. Discussion on clinical safety..............................................................................       | 56                                                                                                        |
| 2.7.2. Conclusions on the clinical safety                                                                                | ...................................................................... 58                                 |
| 2.8. Pharmacovigilance                                                                                                   | ............................................................................................. 58          |
| 2.9. Risk Management Plan........................................................................................        | 58                                                                                                        |
| 2.10. Product information..........................................................................................      | 58                                                                                                        |
| 2.10.1. User consultation...........................................................................................     | 58                                                                                                        |
| 2.10.2. Labelling exemptions                                                                                             | ..................................................................................... 58                  |
| 3. Benefit-Risk Balance                                                                                                  | .............................................................................59                           |
| 4. Recommendations.................................................................................61                    |                                                                                                           |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverse event

ALT

Alanine aminotransferase

ANC

Absolute neutrophil count

ASCO

American Society of Clinical Oncology

AST

Aspartate aminotransferase

bcl

B cell lymphoma

BICR

Blinded independent central reviewer

BUN

Blood urea nitrogen

CBC

Complete blood count

CFR

Code of Federal Regulations

CHOP-R

Cyclophosphamide, doxorubicin, prednisone, vincristine with Rituxan

CI

Confidence  interval

CNS

Central nervous system

CR

Complete response

CRADA

Cooperative Research and Development Agreement

CRu

Complete response unconfirmed

CT

Computed tomography

CTC

Common Toxicity Criteria

CTEP

Cancer Therapy Evaluation Program

DFS

Disease free survival

DSMB

Data safety monitoring board

ECHO

Echocardiogram

ECOG

Eastern Cooperative Oncology Group

eCRF

Electronic case report form

EKG

Electrocardiogram

FCC

Follicular center cell

FDA

Food and Drug Administration

FL

Follicular lymphomas

FLIPI

Follicular Lymphoma Prognostic Index

FM

Follicular mixed lymphomas

FNA

Fine needle aspiration

FNHLId1

Autologous immunoglobulin follicular lymphoma idiotype vaccine (dasiprotimut T Biovest)

<div style=\"page-break-after: always\"></div>

| GCP    | Good Clinical Practice                                                           |
|--------|----------------------------------------------------------------------------------|
| G-CSF  | Granulocyte colony-stimulating factor                                            |
| GI     | Gastrointestinal                                                                 |
| GM CSF | Granulocyte macrophage colony-stimulating factor GMPGood Manufacturing Practices |
| HCG    | Human chorionic gonadotropin                                                     |
| HIV    | Humanimmunodeficiency virus                                                      |
| HLA    | Human leukocyte antigen                                                          |
| ICH    | International Conference on Harmonisation                                        |
| Id     | Idiotypic surface Ig                                                             |
| IDES   | Internet data entry system                                                       |
| IEC    | Independent Ethics Committee                                                     |
| IFN γ  | Gamma-interferon                                                                 |
| IND    | Investigational New Drug Application                                             |
| IPI    | International Prognostic Index                                                   |
| IRB    | Institutional Review Board                                                       |
| ITT    | Intent-to-treat                                                                  |
| IV     | Intravenous (ly)                                                                 |
| IVP    | Intravenous pyelogram                                                            |
| IWG    | International Working Group                                                      |
| KLH    | Keyhole limpet haemocyanin                                                       |
| LBL    | Lymphoblastoid cell lines                                                        |
| LDH    | Lactate dehydrogenase                                                            |
| LFT    | Liver function test                                                              |
| MD     | Maryland                                                                         |
| MedDRA | Medical Dictionary for Regulatory Activities MRI Magnetic resonance imaging      |
| MUGA   | Multiple gated acquisition                                                       |
| NCCN   | National Comprehensive Cancer Network                                            |
| NCI    | National Cancer Institute                                                        |
| NDA    | New Drug Application                                                             |
| NHL    | Non-Hodgkin'slymphoma                                                            |
| NIH    | National Institute of Health                                                     |
| OCT    | Optimal cutting temperature                                                      |
| ORR    | Overall response rate                                                            |
| PACE   | Prednisone, doxorubicin, cyclophosphamide, and etoposide PBMC                    |

<div style=\"page-break-after: always\"></div>

|      | Peripheral blood mononuclear cell             |
|------|-----------------------------------------------|
| PCR  | Polymerase chain reaction                     |
| PD   | Progressive disease                           |
| PHI  | Protected health information                  |
| PI   | Principal Investigator                        |
| PP   | Per protocol                                  |
| PR   | Partial response                              |
| PT   | Prothrombin time                              |
| PTT  | Partial thromboplastin time                   |
| SAE  | Serious adverse event                         |
| SC   | Subcutaneously                                |
| SD   | Stable disease                                |
| SDev | Standard deviation                            |
| SGOT | Serum glutamate oxaloacetic transaminase      |
| SGPT | Serum glutamate pyruvate transaminase         |
| SOC  | System organ class                            |
| SPD  | Sum of the products of the greatest diameters |
| TBI  | Total body irradiation                        |
| TEAE | Treatment emergent adverse event              |
| TIW  | Three times per week                          |
| TNF  | Tumour necrosis factor                        |
| US   | United States                                 |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Biovest  Europe  Ltd  submitted  on  3  December  2013  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Lympreva,  through  the  centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 21 June 2012.

Lympreva, was designated as an orphan medicinal product EU/3/06/394 on 28/08/2006. Lympreva was designated as an orphan medicinal product in the following indication:  Treatment of follicular lymphoma.

The applicant applied for the following indication: Lympreva is an autologous immunoglobulin vaccine indicated for the treatment of patients with follicular non-Hodgkin ' s lymphoma (FL) as first line consolidation therapy after achieving complete remission with induction therapy and is co-administered with Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). Efficacy with induction  therapy  other  than  the  PACE  regimen  (prednisone,  doxorubicin,  cyclophosphamide, etoposide) used in FL patients has been established in mantle cell lymphoma patients (MCL) with the EPOCH-R regimen (doxorubicin, etoposide, vincristine, cyclophosphamide, prednisone, rituximab). Efficacy relative to other first line consolidation therapies has not been established. Lympreva is indicated in adults.

## The legal basis for this application refers to:

Article  8(3)  of  Directive  2001/83/EC  -  complete  and  independent  application.  The  application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/1/2011 on the granting of a class waiver and EMA Decision P/0181/2012 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Licensing status

The product was not licensed in any country at the time of submission of the application.

<div style=\"page-break-after: always\"></div>

## 1.2. Manufacturers

## Manufacturer of the active substance

Biovest International, Inc. 8500 Evergreen Boulevard NW Minneapolis, MN 55433 USA

## Manufacturer responsible for batch release

Propak Health Ltd 3-4 Ballyboggan Industrial Estate Ballyboggan Road, Finglas Dublin Ireland

## 1.3. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Kristina Dunder

Co-Rapporteur:  Jens Ersbøll

CHMP Peer reviewer: Arantxa Sancho-Lopez

PRAC Rapporteur: Brigitte Keller-Stanislawski

- The application was received by the EMA on 3 December 2013.
- The procedure started on 26 December 2013.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 14 March 2014. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 23 March 2014.
- PRAC Rapporteur's Risk Management Plan (RMP) Assessment Report as endorsed by PRAC on 10 April 2014
- During the meeting on 25 April 2014, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 28 April 2014.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 17 October 2014.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 21 November 2014 .
- The Rapporteurs circulated the updated Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 27 November 2014.
- PRAC Rapporteur's Risk Management Plan (RMP) Assessment Report as endorsed by PRAC on 4 December 2014.
- During the CHMP meeting on 18 December 2014, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.

<div style=\"page-break-after: always\"></div>

- The applicant submitted the responses to the CHMP List of Outstanding Issues on 19 February 2015.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 3 March 2015.
- PRAC Rapporteur's Risk Management Plan (RMP) Assessment Report as endorsed by PRAC on 12 March 2015.
- During the BWP meeting on 17 March 2015, the outstanding quality issues were addressed by the applicant during an oral clarification before the BWP.
- During the CHMP meeting on 24 March 2015, outstanding clinical issues were addressed by the applicant during an oral explanation before the CHMP.
- During the meeting on 23 April 2015, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a Marketing Authorisation to Lympreva.

## 2. Scientific discussion

## 2.1. Introduction

## Problem statement

Follicular  lymphoma  (FL),  an  indolent  B-cell  lymphoma,  accounts  for  22%  of  non-Hodgkin's lymphomas (NHL) diagnosed worldwide. The indolent FLs include follicular small-cleaved cell (FSC) and follicular mixed (FM) lymphoma. Stage I and II patients comprise only 10-15% of all cases of FL and are best managed with radiation therapy. Eighty-five percent of newly diagnosed FL patients present with stage III or IV disease, which requires systemic therapy that has the capacity to produce high complete response rates but has failed to prolong overall survival (OS). Over the past decade, the management of lymphoma benefited from a broad range of highly-active first-line (induction) and consolidation therapies for advanced disease requiring treatment (NCCN Guidelines in Oncology, v. 1.2013).

Morphologically, FL is defined as a proliferation of malignant germinal center B cells and the relative proportion of centrocytes to centroblasts underlies the current grading scheme with, at its extremes, grade 1 FL comprising low numbers of centroblasts (0-5 per high-power field) and grade 3B FL marked by solid sheets of these same cells (Kridel et al. 2012). The hallmark t(14;18)(q32;q21) in FL results in constitutive overexpression of the BCL2 protein, allowing B cells to abrogate the default germinal center apoptotic program. Cell surface main markers include CD19, CD20, CD5, CD23 and CD10 (NCCN Guidelines in Oncology, v. 2.2014).

Patients with FL usually present with painless lymph node enlargement involving superficial lymph nodes of small to medium size, sometimes unnoticed by the patients. In some patients there may be no peripheral lymphadenopathy and abdominal or back pain is reported due to deep lymph nodes slow growth, usually in the infradiaphragmatic territories such as the retroperitoneum, the mesenteric, or the  iliac  areas.  Primary  mediastinal  involvement  is  uncommon,  as  well  as  isolated  splenic enlargement. The general status of the patient is usually preserved, with few patients presenting with B symptoms or an altered performance status. Primary involvement of extranodal areas is also very uncommon and when it happens the bone marrow is involved in 50% to 60% of the cases. Some unusual  clinical  presentations  include  particular  cases  with  a  distinct  behaviour  involving  the gastrointestinal tract, the testis and the 'in situ' FL (Goodlad et al. 2004).

<div style=\"page-break-after: always\"></div>

Currently,  approximately  70-90%  of  FL  patients  obtain  remission  following  induction  therapy; consolidation therapies as a class seek to improve the quality of response achieved with first-line regimens (Morschhauser et al. 2008), to extend remission period and prevent relapse. However, even with  these  improvements  largely  due  to  the  addition  of  rituximab  used  as  induction  as  well  as consolidation treatment (Rummel M et al. 2009, Salles et al. 2011), therapies are not curative and median overall survival averages approximately 10 years. Given the median age at diagnosis of FL patients is about 60 years (Rohatiner and T. A. Lister, 2005), the projected ageing of the population in the Western world that will likely render FL a morbidity burden of the elderly, and the essentially symptom free status of FL patients in first remission, developing non-toxic consolidation therapeutic approaches remains highly desirable.

## About the product

Lympreva  is  an  autologous  lymphoma-derived  immunoglobulin  (Ig)  idiotype  (Id)-keyhole  limpet hemocyanin (KLH) conjugate active immunotherapy product manufactured from a patient's lymph node biopsy.The variable regions of the surface immunoglobulin (Ig) on a B-cell form a specific antigen binding site that is unique to each Ig and contain molecular determinants, termed idiotype (Id),  which  can  themselves  be  recognized  as  antigens.  Since  B-cell  malignancies  are  clonal proliferations of cells, the Ig variable regions on the tumour cells are distinct from other normal B cells. The idiotypic determinants of the surface Ig of a B-cell lymphoma can therefore serve as a tumour-specific antigen for therapeutic vaccine development and represent the antigen targeted by Lympreva.

The  mechanism  of  action  appears  to  be  mediated  through  induction  of  idiotype-specific  and tumour-specific T-cell responses. Antigen presenting cells (APCs) process Id-KLH and display Id/KLH peptides on Human Leukocyte Antigen (HLA) class II receptors, which lead to the activation of CD4+ T-cells. Id-specific CD4+ T-cells undergo clonal selection and induce substantial cytokine release (TNF, IFN γ , GM-CSF), activating a wide range of adaptive responses, including B-cell anti-tumour antibody production (mostly IgG1, supposed to specifically recognize and bind autologous tumour cells), memory T-cell induction, and CD8+ T-cell (cytotoxic) responses. Trafficking of activated CD8+ T-cells leads to recognition of tumour cells via Id peptide fragments displayed on MHC-I receptors on the tumour cell surface, which results in tumour cell lysis.

The applicant applied for a marketing authorisation for the following indication: 'Lympreva is an autologous immunoglobulin vaccine indicated for the treatment of patients with follicular non-Hodgkin's lymphoma (FL) as first line consolidation therapy after achieving complete remission with  induction  therapy  and  is  co-administered  with  Granulocyte  Macrophage  Colony-Stimulating Factor  (GM-CSF).  Efficacy  with  induction  therapy  other  than  the  PACE  regimen  (prednisone, doxorubicin, cyclophosphamide, etoposide) used in FL patients has been established in mantle cell lymphoma  patients  (MCL)  with the EPOCH-R  regimen  (doxorubicin, etoposide, vincristine, cyclophosphamide, prednisone, rituximab). Efficacy relative to other first line consolidation therapies has not been established. Lympreva is indicated in adults.'

However during the procedure the applicant changed the applied indication to : ''Lympreva is an active immunotherapy indicated for the treatment of patients with follicularnon-Hodgkin's lymphoma (FL)  as  consolidation  therapy  after  achieving  complete  remission  with  induction  therapy  and  is co-administered with Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). For information on the induction therapy used in clinical trials see section 5.1''.

The recommended dose is 1 mg autologous tumour-derived immunoglobulin Id coupled with KLH administered subcutaneously on day 1 and accompanied by 100 micrograms/m²/day, or 5.6 times the  105  IU/m 2 ,  of  sargramostim  (GM-CSF)  administered  subcutaneously  on  days  1-4.  The recommended course of treatment is 5 doses administered over 6 months, at month 1, 2, 3, 4, and 6.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

Lympreva is an autologous immunoglobulin idiotype (Id) active immunotherapy product designed to stimulate an immune response against Id, a tumour specific surface antigen, which leads to tumour cell lysis and elimination of residual follicular lymphoma (FL) cells. This patient-specific protein active immunotherapy product is prepared by hybridoma technology, where the patient's lymphoma cells are  fused  to  a  human-mouse  heteromyeloma  cell  line  in  order  to  produce  the  tumour  specific immunoglobulin Id protein. The immunoglobulin is purified from the culture supernatant by affinity chromatography, conjugated to an immunogenic carrier protein, keyhole-limpet haemocyanin (KLH) and administered together with Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) as an adjuvant.

Each single-use 2 mL vial of Lympreva contains 1 mg dasiprotimut-T per 1 mL of sterile frozen clear suspension in 0.9% sodium chloride solution.

## 2.2.2. Active Substance

## General information

The chemical name is Follicular lymphoma-derived immunoglobulin idiotype protein conjugated to keyhole limpet haemocyanin.

Lympreva is a Follicular lymphoma-derived immunoglobulin idiotype protein conjugated to keyhole limpet haemocyanin. The active pharmaceutical ingredient in dasiprotimut-T is the patient's unique idiotype protein conjugated to keyhole limpet haemocyanin (KLH).

Dasiprotimut-T is comprised of two biological substances: an autologous immunoglobulin molecule (IgM or IgG) conjugated to KLH from the mollusc Megathura crenulata (keyhole limpet). Idiotype protein structure differs from patient to patient (lot-to-lot).

Autologous Idiotype (Id) is an immunoglobulin of the IgM or IgG isotype containing the idiotype expressed by a patient's  follicular  lymphoma  tumour  cell.  The  idiotype  is  purified  from  the  bulk supernatant  of  hybridoma  clone  and  specific  to  the  tumour  biopsy  cells  from  which  it  was manufactured. Therefore physicochemical properties will vary from patient to patient. The biological activity of dasiprotimut-T is determined by its identity and purity.

KLH  is  a  blue,  copper-containing  oligomeric  glycoprotein  from  the  mollusc Megathura  crenulata (keyhole limpet). The two subunit isoforms, KLH  1 and KLH  2, associate into multiple homo-oligomeric  structures.  The  molecular  weights  predicted  for  the  KLH  1  and  KLH  2  subunit isoforms from their peptide sequences are approximately 391,000 and 392,000 Daltons, respectively. Actual molecular weights are variable due to differential glycosylation of the proteins, which may account for 4% of the mass. Both isoforms contain N-acetylglucosamine, N-acetylgalactosamine, galactose, mannose, and fucose. The carbohydrates moieties are believed to be important to enhance immunogenicity of KLH. The large number of available lysine residues in KLH facilitates conjugation when used for production of conjugates.

## Manufacture, characterisation and process controls

Description of manufacturing process, process controls and validation

The patient-specific component of dasiprotimut-T consists of an immunoglobulin of either an IgG or IgM isotype, which defines the specific process used to purify the Id. The purified immunoglobulins

<div style=\"page-break-after: always\"></div>

(Id) are conjugated to keyhole limpet haemocyanin (KLH) using glutaraldehyde. The whole mixture is dialysed against physiological sodium chloride solution.

Manufacture  starts  with  the  isolation  of  patient  tumour  cells  from  a  lymph  node  biopsy  of  a non-Hodgkin's lymphoma patient who may receive treatment with dasiprotimut-T and subsequent fusion of the cryopreserved biopsy cells with a heteromyeloma cell line.

Manufacture of dasiprotimut-T is segregated into two principle parts: (1) Production and purification of the Id (autologous immunoglobulin) and (2) conjugation of purified Id to KLH.

The patient-specific component of dasiprotimut-T consists of an immunoglobulin of either an IgG or IgM isotype, which defines the specific process used to purify the Id. The purified immunoglobulins (Id) are conjugated to keyhole limpet haemocyanin (KLH) using glutaraldehyde.

The purification process includes a series of chromatography, viral inactivation and filtration steps.

Process evaluation studies were conducted on the dasiprotimut-T manufacturing process to determine methods, operating parameters, in-process controls, and consistency of the process. The operating parameters are used in the ongoing validation studies.

## Control of materials

All raw materials were sourced from approved suppliers, Certificates of Analysis were presented and TSE certificates submitted where relevant.

## Patient biopsies:

A description of the handling of patient biopsies has been included in the dossier. Information on in-process testing for biopsy processing and cryopreservation is given. The procurement and testing of biopsies should be in line with the EU Directive (2004/23/EC) for tissues and cells. This therefore needs to be confirmed and specifications for testing, including virus testing of biopsies, should be presented.  The  patients  are  screened  for  HIV  and  Hepatitis  B.  However,  according  to  Directive 2006/17/EC, donors should at least be tested on HIV-1, HIV-2, Hepatitis B, Hepatitis C and Syphilis. Biovest commits to perform testing in line with the Tissue and Cell Directive when the first commercial batches will be manufactured and the formal requirements in line with the Tissue and Cells Directive will be followed. To date no new biopsies have been procured, stored and tested but the plan to fulfil the requirements is acknowledged. No biopsy processing validation has been performed and the plan is to do this on an ongoing basis for commercial production or clinical trials. The cause of the failure of five patient's biopsies has been presented and is sufficiently clarified (IgG3 could not be purified (for 2 batches), failed fusion step with K6H6 cells, failed supernatant step, unable to make finished product in time).

## Cell banks:

A cell  banking system exists for the fusion partner cell line consisting of a MCB and WCBs. The K6H6/B5 cells were produced from a fusion of malignant lymphoid cells from a patient with nodular lymphoma with a mouse myeloma line. The source of the cells, the history and cell banking has sufficiently been described. The testing of the MCBs is found acceptable. The WCB are tested for Purity, Identity, Cell Growth, Cell Viability and Fusion capability. The WCB is also tested for its ability to fuse with human lymphocytes each time a fusion process is conducted for individual patients.

<div style=\"page-break-after: always\"></div>

## Manufacturing Process Development

## Process 1

The dasiprotimut-T manufacturing process begins with a lymph node biopsy from a non-Hodgkin's lymphoma  patient  who  may  receive  treatment  with  dasiprotimut-T.  The  active  pharmaceutical ingredient  (API)  in  dasiprotimut-T  is  the  patient's  unique  idiotype  protein  conjugated  to  the immunogen keyhole limpet haemocyanin (KLH). Each autologous, conjugated protein constitutes a unique lot and is specific to an individual patient. This manufacturing process was used to prepare supplies for the Phase 2 and Phase 3 studies.

## Process 2

The commercial manufacturing process proposed for dasiprotimut-T (Process 2) has been changed since the conduct of the BV301 Phase 3 clinical trial.

The  development  of  the  manufacturing  process  includes  an  upgraded  bioreactor  to  provide automated control of the cell culturing steps. Purification process changes were put in place in order to reduce host cell proteins, improve process robustness and improve viral clearance resulting in higher product purity. These changes were also made to minimize lot-to-lot variability of the idiotype protein  and  improve  manufacturing  consistency.  Data  to  date  indicate  that  the  process  changes impact impurity levels, including host cell protein (HCP) levels and DNA levels. Manufacturing Process 2 has been used for development batches and reference standard generation and is the proposed process for commercial manufacture.

## Characterisation:

Idiotype  protein  structure  differs  from  patient  to  patient  (lot-to-lot).  According  to  Biovest,  the autologous  product  is  administered  as  one  therapeutic  course  and  therefore  detailed  structural characterisation of each patient-specific protein is not necessary. Although the autologous protein is an immunoglobulin, Dasiprotimut-T acts as active immunogen and not as antigen-binding monoclonal antibody. Thus, affinity/avidity and other biological characteristics that commonly define antibodies are not considered relevant for the mechanism of action. The essential properties of dasiprotimut-T are Identity, Purity and extent of Conjugation.

For characterisation analytical methods and results of studies using three batches manufactured during 2013  are described. Analytical methods  comprise release methods  and additional characterisation procedures.

Nucleotide sequence analysis and fusion IgH fingerprinting product was performed on patient biopsy cells and the patient hybridoma Production Clone. The amplimer strategy to amplify the same VH sequence from cDNA as well as genomic DNA template is demonstrated to be acceptable. Data to demonstrate suitability of this approach for establishing identity has been provided.

The purified Id (IgM or IgG) and KLH are conjugated via glutaraldehyde resulting in a solution containing a combination of three products: Id-KLH, Id-Id, or KLH-KLH. The Extent of Conjugation test demonstrates that Purified Id is conjugated to keyhole limpet haemocyanin. An improved method for the extent of conjugation is being developed based on immunoprecipitation and flow cytometry. A complete evaluation of extent of conjugation remained to be provided (see discussion).

Determination of potency through direct measurement of immunogenicity will not be possible as the patient's  immune  system  is  not  naïve  to  the  molecule  and  HLA  differs  from  person  to  person. Therefore, the potency is controlled indirectly via the monitoring of identity, purity and conjugation. For  this  approach  to  be  acceptable,  release  testing  would  have  to  be  extended  based  on  the characterisation study. In the characterisation study a biological activity study should be used to evaluate  the  impact  of  various  quality  parameters.  Additional  analytical  data  would  have  to  be provided to ensure consistency of the composition of the conjugate (see discussion).

<div style=\"page-break-after: always\"></div>

Due to the nature of the product and its inherent variability, the introduced specification set to at least 50% for Id-containing proteins also containing KLH is deemed acceptable.

The purity of the Purified Id is monitored in-process.

Possible product-related impurities have not been identified nor quantified for dasiprotimut-T.

Potential process-related impurities have been identified and methods to quantify levels of those impurities have been developed. Still few batches have been analysed and only development batches have been produced recently.

## Specification

The specifications for the active substance were provided.

Validation of analytical methods was ongoing in 4 stages of development and has been completed.

## Batch Analysis

Each patient-derived cell line, or autologous hybridoma, is unique relative to growth and Id secretion rates.  These  variations  between  individual  hybridoma  clones  lead  to  differing  culture  durations (Hybridoma  Expansion)  and  crude  supernatant  harvests  containing  a  range  of  Idiotype  protein concentrations. This can affect process performance during purification and therefore the process is closely monitored. The majority of the critical testing required takes place at or before the purified Id stage which may be acceptable only if the extent of conjugation can be monitored quantitatively. Demonstration  of  compliance  with  specifications  for  Critical  Quality  Attributes  remained  to  be provided (see discussion).

## Reference Standards

Reference Standards were designed to represent both IgG as well as IgM isotypes and to serve as references for testing of Purified Id and Id-KLH Conjugates. It has been confirmed that the reference standards originate from Process 2 material. Their suitability to work as reference standards needs to be confirmed by process validation (and comparability) data.

## Container closure system

The active substance Dasiprotimut-T manufactured at Biovest (Minneapolis, MN) is filled immediately into clear glass vials to form the Lympreva Finished product. A process intermediate, Purified Id, is proposed to be held in Flexboy® bioprocessing bags for up to 7 days at 2-8°C.

It is stated that Quality Assurance for Flexboy bioprocessing bags follows applicable ISO and FDA regulations for Medical Devices. The suitability of the packaging components for Purified Id will be determined by an Extractables/Leachables study and a Photostability study by a contract laboratory.

The results of the study showing the suitability of the packaging are deemed acceptable.

## Stability

Stability data demonstrate that there are no significant changes in IgM or IgG Purified Id after storage for one week at 2-8°C (parameters remained within specification limits and/or acceptance criteria). Bulk Id may be held for up to 45 days at 2-8°C or -60 to -80°C (parameters monitored remained within specification limits and/or acceptance criteria). The proposed shelf life for Purified Id is one week at a storage temperature of 5±3°C. Stability data support the proposed shelf life.

It is stated that all past stability results are being provided as developmental data to support future stability studies that will be designed to stand on their own.

Protocols for Bulk Id IgG and IgM were provided and the stability study is performed at the proposed

<div style=\"page-break-after: always\"></div>

storage temperature  (-20°C).  The  protocols are not deemed  scientifically  sound,  because investigated parameters (like residual process related impurities) seem to be irrelevant (i.e. are not expected to change during storage) and relevant parameters (e.g. identity and degradation - i.e. to demonstrate  an  intact  immunoglobulin)  are  not  tested.  Requested  methods  (Reduced  and Non-reduced SDS-Page both followed by silver staining and Western Blotting as well as Size-exclusion HPLC) had not been implemented in either stability protocol. (see discussion)

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Lympreva is a pale yellow suspension with small white to off-white precipitates.

The composition of Lympreva is presented in the following table:

| Component       | Function          | Quality Standard              | Quantity mg/ vial   |
|-----------------|-------------------|-------------------------------|---------------------|
| Id-KLH          | Active Ingredient | Manufacturer's specifications | 1.1 mg/vial         |
| Sodium chloride | Diluent           | USP/Ph. Eur                   | 9.9 mg/vial         |

Lympreva is supplied as one individual patient-specific dose of 1.0 mL suspension contained in a clear glass vial in a pack size of five. Each vial contains 1.0 mL of autologous Lympreva. The formulation is the same as used during the clinical study.

All compendial excipients conform to EP monographs.

The  finished  product  is  administered  together  with  Granulocyte  Macrophage  Colony-Stimulating Factor (GM-CSF) in one syringe. The applicant was requested to a) demonstrate that these two drugs are compatible when co-administered in one syringe, b) to establish the in use shelf life of 6 h for both Dasiprotimut-T Biovest and GM-CSF and c) to include in the SmPC the GM-CSF products for which this has been established (see discussion).

## Manufacture of the product and process controls

The active substance is directly processed into finished product. The representative batch formula for Lympreva is presented (33 mg of Dasiprotimut and 9 mg NaCl/mL). The quantities of each component are based on a typical batch size of 30 vials.

The manufacturing process of the finished product consists of manual aseptic filling of the finished product in glass vials, stoppering, capping and crimping. Information on washing, sterilisation and depyrogenation of vials and stoppers has been provided.

Qualification of the aseptic filling process using media fills and evaluation of fill volume using an aseptic mock-fill has been performed and found acceptable.

Available data from IgM process validation batches have been included in the dossier as appropriate, but a complete data set including finished product testing has not yet been provided. A prospective process validation for Lympreva manufacture will be performed for six unique lots of patient-specific Lympreva. These validation batches will represent the process used for commercial manufacture and conform to the specifications set for release of Lympreva. No data from the prospective study have been attached to the dossier (see discussion).

<div style=\"page-break-after: always\"></div>

## Product specification

The specification of Lympreva was presented.

Lympreva is comprised of an autologous tumour-derived idiotype (Id) protein coupled to keyhole limpet haemocyanin (KLH). Unique product lots are manufactured for each patient. The variation from patient  to  patient  necessitates  broader  specifications  for  certain  aspects  of  the  active  substance properties than those used for non-autologous biologicals. The majority of testing is performed before the filling stage on the active substance dasiprotimut-T. Release testing for clinical batches included.

Most analytical methods proposed to release Lympreva are compendial methods.

Each batch of finished product is tested for extractable volume, requiring 5 vials. A description of the sterility test is provided.

## Container closure system

Lympreva is filled into Type I, clear glass vials and sealed with a Teflon-faced rubber stopper secured with an aluminium flip-off over seal.

Container and closure integrity testing is stated to be performed as part of the stability studies on the validation batches (process validation). Sterility testing is stated to be performed as part of the initial stability studies indicated that the container/closure system remains intact and functional during storage. Confirmation of the initial results was awaited from the planned process validation studies (see discussion).

## Stability of the product

Twelve months stability data are presented for eight batches of Lympreva manufactured on a pilot scale at NCI and Biovest. These were filled into the proposed commercial container/closure Type I, clear glass vials and sealed with a Teflon-faced rubber stopper secured with an aluminium flip-off over seal.

The results of the real time studies demonstrate the stability of Lympreva when stored at 12 months at -20 ± 4°C. No significant changes were observed in percent purity by SDS-PAGE and western blot, sterility, or endotoxin. All results complied with the release and/or end of life specification in place at the time of the study.

Studies assessing the stability of Lympreva were performed at multiple sites during the Phase III trial. The stability analytical studies performed were SDS-PAGE and Western Blots to assess the degree of protein degradation over time at various storage temperatures. Sterility and endotoxin assays were performed. Stability data are available up to 26 months, under various temperatures.

The early stability data are the property of NCI and a summary of these data is provided. The clinical trial batches were manufactured using Process 1, which differs from the proposed commercial process in the purification steps. The filling procedure has not changed.

The stability protocol to assess the stability of Lympreva for the commercial validation batches is provided.

The shelf life is stated to having been shortened to 6 months (from 24 months) at -20ºC. For this shortened shelf life it was confirmed that the treatment period allows such a short shelf life. Still, no data on stability of the commercial batches has been presented. Thus, adequate stability data for the finished product have not been provided and the proposed shelf life is therefore not justified with data (see discussion).

## Adventitious agents

All raw materials used were sourced from approved suppliers and determined to be absent of viral and non-viral adventitious agents, including Transmissible Spongiform Encephalopathies.

<div style=\"page-break-after: always\"></div>

Certificates  of  Analysis  (COA)  for  all  biological  raw  materials  have  been  presented  including Certificates of Suitability establishing compliance with monographs of the European Pharmacopoeia (CEP)  and  materials  of  animal  origin  in  compliance  with  Directive  75/318/EEC  (Tables  A-C)  are provided. Non-irradiated Fetal Calf Serum is no longer used in the cell culture. TSE certificates were provided.

The viral clearance studies have not been finalised. The viral safety for the IgM process is deemed insufficient. Results for the IgG virus clearance studies were still awaited.

Data in support of microbiological safety derive from in-process controls and testing of the biopsy. However, virus testing fully in compliance with EU Directives 2004/23/EC and 2006/17/EC has not been performed on the biopsies to date (see discussion).

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Points that have been resolved or partly resolved at time of opinion are:

- The formal requirements in line with the Tissue and Cells Directive (2004/23/EC) will be followed (e.g.  procurement,  storage,  testing,  shipping,  labelling).  To  date  no  new  biopsies  have  been procured, stored or tested. The plan is to fulfil the requirements and to conduct biopsy-processing validation on an on-going basis. The protocol for biopsy processing validation has been presented and is  acceptable.  Biopsy  processing  validation  will  be  done  on  an  ongoing  basis  for  commercial production or clinical trials. .

-  Biopsy processing and handling have been outlined and validation reports for fusion and clone selection have been presented. Pending results from process validation batches and the comparability study, along with clinical batch data, are supposed to support batch analysis.

-  Analytical  procedures  have  been  validated  with  reference  to  ICH  Q2(R1)  and  requests  for clarifications and updates of procedures have been responded to and found acceptable.

-  Two  tests  for  finished  product  release  testing  have  been  added.  Validation  of  the  assays  was sufficiently shown.

- The protocol of the IgG viral clearance study is considered adequate, but the study has not been completed. The results on the Master  Cell Bank testing program are pending. Even though  TSE certificates were not required at the time of MCB#1 establishment and suitable gamma-irradiation of BSA for MCB#2 establishment cannot be assured, the justification can be accepted due to the testing for bovine viruses and mycoplasma as well as further testing of the MCB.

Oral Clarification on Quality Outstanding Issues at BWP (14/04/15):

An oral presentation was given by the Applicant concerning the unresolved major issues identified. From the presentation in which no new data were presented it is clear the applicant is working very focussed on resolving the outstanding issues and this work was acknowledged. Time frames were presented for the different outstanding issues and respective updates regarding ongoing studies were also presented at CHMP.  Most validation studies are claimed to be finished in the near future. It was however considered that the results of these studies need to be assessed and found acceptable before a  positive  opinion  can  be  given.  The  issue  concerning  validation  of  the  biopsy  processing  was discussed after the oral presentation which resulted in a modified conclusion on the unresolved issue on biopsy procurement / storage / testing and validation according to the Tissue and Cells directive.

<div style=\"page-break-after: always\"></div>

At time of opinion there are the following major issues related to the quality aspects of the product and their potential impact on efficacy and safety:

Full access to pertinent information from the supplier can be considered as assured but the definition of  KLH  as  starting  material  is  ambiguous  and  not  endorsed.  Neither  manufacturing  process  nor analytical methods have been validated and Critical Process Parameters (CPPs) have not been laid down or justified. Completed stability studies on KLH in line with ICH-recommendations are lacking and shelf life as well as storage conditions for vialled KLH (to be supplied to the user) have not been addressed. Stability  data  presented  are  incomplete  and  the  battery  of  analytical  methods  is  too limited.

Several tests for characterisation have not been qualified (see discussion).

Data  from  comparability  assessment  between  Process  1  (clinical  trials  material)  and  Process  2 (commercial process) are deemed insufficient.

Process-related  impurities  are  insufficiently  controlled  because  the  removal  is  not  validated  and specifications are based on incomplete data.

Demonstration of CQA's being within specifications despite large yield differences due to variability between individual batches should have been provided. Reference is made to EMA/CHMP/BWP/187338/2014 ('Process  validation  for  the  manufacture  of  biotechnology-derived active substances and data to be provided in the regulatory submission').

Correct and scientifically sound stability protocols were lacking. For Bulk Id IgG and IgM further tests (e.g. reduced and non-reduced SDS-PAGE using silver staining and Western Blotting, size exclusion HPLC and other tests for control of Id protein) besides the proposed ones are required.

Adequate stability data (collected with validated methods) for finished product manufactured with the commercial process have not been provided. A six-month shelf life  has  been  implemented  as  a conservative estimate and the shelf life will be extended when stability data are generated.

Results of compatibility studies supporting the instructions for use (co-administration of Lympreva and GM-CSF in one syringe; in use shelf life) and handling in the SPC have been requested. The requested study is still pending, thus the issue is persisted and was included as a MO at D180 due to the risk of implications on safety and efficacy of the product.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

In  conclusion,  based  on  the  review  of  the  quality  data  provided,  the  CHMP  considers  that  the marketing authorisation application for Dasiprotimut-T is currently not approvable from the quality point  of  view  since  major  objections  still  remain  that  preclude  a  recommendation  for  a  positive opinion.

The outstanding Major Quality Objections are as following:

- -The quality of the critical intermediate KLH was insufficiently guaranteed. The CTD section dealing with the critical intermediate KLH is deemed deficient and incomplete. A major issue was the lack of process validation.
- -The manufacturing process lacked full process validation and sufficient control of bioburden.
- -Viral clearance and viral inactivation data for the IgM and IgG processes was insufficient and therefore, a final conclusion on viral safety cannot be drawn.
- -Comparability between material from the manufacturing process used for clinical batches and

<div style=\"page-break-after: always\"></div>

material from the commercial manufacturing process had not been demonstrated as studies were incomplete.

- -Process related impurities are insufficiently controlled as specifications with associated actual limits were not defined and analytical methods for their determination were not validated.
- -Characterisation  data  are  incomplete  and  several  characterisation  tests  had  not  been qualified.
- -Critical Quality Attributes should be within specifications, despite large yield differences due to variability between batches, this has not been demonstrated.
- -Stability:  Stability  for  bulk  IgM  and  IgG  during  shelf  life  had  not  been  demonstrated.  In addition, stability for the medicinal product manufactured with the commercial process had not been demonstrated.
- -Compatibility of the product with regards to the instructions for use and handling in the proposed Summary of product characteristics (co-administration of Lympreva and GM-CSF in one syringe; in use shelf life) had not been demonstrated.

## 2.2.6. Recommendation(s) for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The non-clinical part of this application is based on published literature and no additional study reports have been submitted by the Applicant. All pharmacological experiments were proof of concept studies and were not GLP-compliant.

Scientific advice has not been sought for the non-clinical aspects of Lympreva.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

Pharmacologic  data  were  generated  in  murine  models  using  tumour-specific  Ig  (idiotype,  or  Id) clonally expressed by B-cell lymphomas as unique tumour-specific antigens. The models used were the 38C13 B cell lymphoma, the BCL1 lymphoma, and the lymphoma 141 models.

An overview of the published non-clinical proof of concept studies presented for the application on Lympreva is shown in Table 1.

<div style=\"page-break-after: always\"></div>

Table 1: Overview of relevant primary pharmacodynamics studies

| Type of Study    | Reference              | Objective                                                                                       | Species/Stra in   | Test article                                                                                                          | Method of adninistration   |
|------------------|------------------------|-------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------|
| Proof of concept | (Kaminski et al. 1987) | Assess optimal conditions of immunization                                                       | Mouse / C3H/HeN   | 50 mcg free 38C13-Id; 50 mcg 38C13-Id- KLH                                                                            | i.p.                       |
| Proofof concept  | (Campbell et al. 1987) | Assess whether 38C13-Id-KLH protects against tumour challenge                                   | Mouse / C3H/HeN   | 50 mcg 38C13- Id-KLH in FCA. boosted with same dose in PBS 2 weeks later                                              | i.p.                       |
| Proofof concept  | (Campbell et al. 1988) | Assess therapeutic effects of 38C13-Id- KLH after lethal tuumour inoculation                    | Mouse/ C3H/HeN    | 50 mcg 38C13- Id-KLH in SAF- 1, boosted 1 and/or 2 weeks later                                                        | $.C.                       |
| Proof of concept | (Campbell et al. 1990) | Assessing humoral and cellular requirements for anti- tumour immunity                           | Mouse / C3H/HeN   | 50 mcg 38C13- Id-KLH in SAF- 1, boosted 1 and/or 2 weeks later                                                        | S.C.                       |
| Proofof concept  | (Kwak et al. 1996)     | Assess cytokines / GM-CSF for enhancement of T- cell mediated immune response                   | Mouse / C3H/HeN   | 50 mcg 38C13- Id-KLH (s.c.. i.p.) or 25 mcg 38C13-Id-KLH (i.d.), with and without cytokines                           | s.c., i.p., i.d. (footpad) |
| Proofof concept  | (Heyfets et al. 2002)  | Determination of idiotype-specific T cell response                                              | Mouse / C3H/eB    | 25 mcg 38C13- Id-KLH in CFA two weeks later boosted with similar dose in IFA                                          | $.C.                       |
| Proof of concept | (George et al. 1988)   | Assess whether vaccination has a tumour inhibiting effect and protects against tumour challenge | Mouse / Balb/C    | 50 mcg BCL1 IgM or 50 mcg BCL1 IgM-KLH                                                                                | $.C.                       |
| Proofof concept  | (Sugai et al. 1974)    | Assess whether vaccination has a tumour inhibiting effect and protects against tumour challenge | Mouse / B/W       | 1 mg IgM 141, 104E or human IgM or bovine serum albumin in FCA (total dose, given as 3 weekly or biweekly injections) | s.c.(multiple sites)       |

## 38C13 B cell lymphoma

Immunization of animals with isolated Id protein (i.e., Id from 38C13, a B-cell lymphoma of C3H origin) resulted in the induction of Id-specific resistance to the tumour growth (Kaminski et al., 1987). 38C13  Idiotype  was  isolated  from  ascites  fluid  of  mice  inoculated  with  the  rescue  hybridoma 38C13/A1-2, which secretes abundant quantities of the 38C13 IgM protein. After intraperitoneal (IP) administration  of  purified  Id,  no  detectable  antibody  to  idiotype  was  induced.  Due  to  the  weak

<div style=\"page-break-after: always\"></div>

immunogenicity  of  the  38C13  IgM  protein  alone,  immunisation  with  38C13  conjugated  with  the immunogen keyhole limpet haemocyanin (KLH) was tested and resulted in high titres of anti-Id antibodies.

When mice were lethally challenged with tumour cells IP, mice receiving the Id-KLH experienced 90% long  term  survival  as  compared  with  a  20%  survival  rate  for  mice  receiving  an  irrelevant  (not tumour-derived) IgM conjugated to KLH, demonstrating idiotype-specific immunization. With tumour challenges of 1000 cells and 10,000 cells, the group receiving the Id-KLH demonstrated survival rates of 50% and 20%, respectively. However, of mice receiving the irrelevant IgM-KLH, none survived long-term with either tumour cell number challenge. It was found that the Id-KLH conjugate could produce tumour immunity and antibody responses if it was administered at least one week prior to tumour challenge. The effect of free Id protein on the immunity induced by Id-KLH was investigated and it was  found that free Id blocked immunity; however, once free Id fell to a sufficiently low level, immunity was again induced.

Campbell  et  al.  (1987)  examined  the  humoral  and  cellular  immune  responses  elicited  by  Id immunisation.  Survival  significantly  improved  in  mice  groups  receiving  KLH-conjugated  38C13 idiotype protein compared with mice immunized with an unrelated IgM. Tumours developed in all control animals, while 30% of immunized mice remained tumour free for &gt;120 days. Without KLH as a carrier, 38C13-Id did not confer resistance to tumour challenge and yielded only one long-term survivor. These results provided further support that KLH is needed to generate an adequate immune response to the 38C13 Id protein.

Use of idiotype immunotherapy in a therapeutic-like setting in which some tumour debulking would be expected  with  chemo-  or  radiotherapy,  was  investigated  by  Campbell  et  al.(  1988),  After administration of immunotherapy in the form of idiotype immunisation, mice treated with Id-KLH again demonstrated a significant prolongation on survival as compared with untreated animals. The results showed that Id immunotherapy alone or in combination with chemotherapy can be effective against established B cell tumours.

The roles of humoral and cellular anti-tumour immune responses were investigated in the 38C13 model (Campbell et al. 1990; Heyfets et al. 2002; Kwak et al. 1996). Id-specific T cells had not been found in earlier studies. As survival of T cell subset depleted mice was still significantly longer than the mice immunized with control IgM, it was hypothesized that an antibody dependent mechanism and not T cell responses were most likely responsible for the survival benefit. From tumour implantation experiments (Campbell et al. 1990) it was concluded that humoral responses as well as cellular immunity, which may be needed to produce an adequate humoral response or to lyse tumour directly, are important for resistance to tumour growth.

To determine the effect of a compromised immune system on Id immunotherapy, Kwak et al. (1990) investigated  the  use  of  idiotype  immunization  in  the  bone  marrow  transplant  setting.  Initial experiments showed that lethally irradiated mice transplanted with syngeneic marrow can mount a response to KLH as early as 3 weeks post-transplant. Near full resistance to tumour challenge was restored in mice at 5 weeks post bone marroe transplant. Anti-Id antibody response could be boosted by a second immunization two weeks later, but this did not result in any additional protection against tumour.

Based on the known pleiotropic effects of GM-CSF, including augmentation of antigen presentation, enhancement of T cell proliferation, and induction of MHC Class II expression on monocytes, the ability of GM-CSF to enhance the immune response after Id vaccination was tested in the 38C13 model (Kwak et al. 1996). Mice receiving recombinant murine GM-CSF and challenged with 38C13 tumour  cells  two  weeks  after  immunization  demonstrated  significantly  prolonged  survival  as compared with mice not receiving GM-CSF. GM-CSF administered subcutaneously (SC) appeared more  effective  than  systemic  (IP)  administration,  and,  interestingly,  the  effect  was  found  with relatively low doses of GM-CSF and lost with higher doses. Whereas GM-CSF enhanced survival for

<div style=\"page-break-after: always\"></div>

38C13-Id vaccinated mice, it did not enhance survival for mice administered control IgM-KLH; thus GM-CSF appeared to enhance specific anti-Id immunity.

The involvement of a T cell component to the benefit conferred by GM-CSF was investigated by Kwak et al. (1996). Mice were vaccinated with 38C13-Id-KLH plus GM-CSF for four days, depleted of their CD4+ or CD8+ T cells and challenged with 38C13 tumour cells three weeks after immunization. Consistent with previous experiments, the protective effect of 38C13-Id-KLH was augmented by GM-CSF as compared with Id-KLH  alone.  Depletion  of  either  CD4+  or  CD8+  T  cells  resulted  in abrogation  of  the  beneficial  effect  of  GM-CSF,  indicating  that  the  protective  effect  of  GM-CSF combined with Id-KLH immunization was dependent on CD4+ and CD8+ T cells. Depletion of CD4+ T cells did not influence the beneficial effect of Id-KLH vaccine alone; however, depletion of CD8+ T cells did  abrogate  the  beneficial  effect  of  Id-KLH  vaccination  without  GM-CSF,  indicating  that  the mechanism of action of Id-KLH immunization may be mediated through CD8+ T cells even in the absence of GM-CSF.

An increase in the frequency of Id-specific IFNγ secreting T cells was demonstrated in mice immunized two times with syngeneic 38C13 tumour-derived Ig-KLH (Heyfets et al. 2002). Depletion of T cell subsets demonstrated that both CD4+ and CD8+ T cells were involved in the response to Id. The same  immunization  schedule  resulted  in  high  levels  of  anti-Id  antibodies  and  anti-Id  antibody production was evident already after a single immunization, suggesting a slow onset of the cellular response compared to the humoral response.

## BCL1 mouse model

George et al. (1988) used a slower-growing model of lymphoma, the BCL1 mouse model, to attempt to  come closer to mimicking human disease; the lymphoma grows more slowly than the 38C13 model, allowing for immunization of animals after tumour establishment in the spleen. Instead of varying the time from tumour inoculation, the investigators varied the numbers of tumour cells in the inoculum, which results in replacement of normal spleen cells with tumour cells at different times and allows discernment of the timing of protective immunization. Mice were immunized with BCL1 IgM or BCL1 IgM-KLH and long-term survival was found to be dependent on the number of tumour cells inoculated. In a subsequent study, conjugation of KLH to BCL1 IgM led to a more rapid production of antibodies.

## Lymphoma 141 model

Sugai et al. (1974) investigated the ability of another tumour idiotype, from a spontaneously arising malignant lymphoma murine model in B/W mice (lymphoma 141), to serve as a tumour specific antigen.  They  first  demonstrated  the  presence  of  idiotypic  determinants  on  the  protein  with  an immunofluorescent  assay  using  rabbit  serum  raised  to  the  protein.  Results  from  inhibition experiments showed that purified IgM from the lymphoma 141 cells inhibited binding of the rabbit anti-Id antibodies, whereas an immunoglobulin from another tumour line, MOPC104E, had no effect. When mice  were  immunized  with  a  human  monoclonal  IgM  from  a  patient  with  Waldenstrom's macroglobulinaemia, and challenged with 1 x 105 lymphoma 141 cells, 15/16 mice died by day 35. In contrast, four out of five mice immunized with the lymphoma 141 idiotype had only a small tumour nodule on day 35.

## Secondary pharmacodynamic studies

No secondary pharmacodynamics studies have been conducted with Dasiprotimut-T (see discussion on non-clinical aspects).

## Safety pharmacology programme

Safety pharmacology studies were not performed (see discussion on non-clinical aspects)..

<div style=\"page-break-after: always\"></div>

## Pharmacodynamic drug interactions

Pharmacodynamic drug interaction studies were not performed (see discussion on non-clinical aspects).

## 2.3.3. Pharmacokinetics

Pharmacokinetic studies were not submitted (see discussion on non-clinical aspects).

## Toxicology

## Single dose toxicity

No single-dose toxicity studies were submitted (see discussion on non-clinical aspects).

## Repeat dose toxicity

No repeat-dose toxicity studies were submitted (see discussion on non-clinical aspects).

## Genotoxicity

No genotoxicity studies were submitted (see discussion on non-clinical aspects).

## Carcinogenicity

No carcinogenicity studies were submitted (see discussion on non-clinical aspects).

## Reproduction Toxicity

No reproductive and developmental studies were submitted (see discussion on non-clinical aspects).

## Toxicokinetic data

N/A

## Local Tolerance

No local tolerance studies were submitted (see discussion on non-clinical aspects).

## Other toxicity studies

N/A

## 2.3.4. Ecotoxicity/environmental risk assessment

No ERA was submitted (see discussion on non-clinical aspects).

## 2.3.5. Discussion on non-clinical aspects

Id  immunotherapy  was  associated  with  prevention  or  slowing  the  growth  of  syngenic  tumour challenge in a number of B cell lymphoma models (38C13, BCL1 and lymphoma 141. The addition of the KLH carrier protein added to the Id immunogenicity. The addition of GM-CSF at low i.p. doses showed enhanced protective anti- tumour immunity.

In vitro data generated from immunized animals showed the formation of anti-Id antibodies after vaccination.  The  serum  titres  of  such  antibodies  were  also  correlated  to  survival.  Serum  from immunized animals was also able to induced ADCC against the syngenic tumour. A specific T cells response against the Id antigen was also shown by a decrease in tumour protection in immunised, T cell depleted, animals after tumour challenge. Also, upon prime-boost immunisation IFNg producing T cells could be detected upon Id-antigen stimulation. In addition, mice with a compromised immune system (lethally irradiated and transplanted) were able to survive tumour challenge after receiving Id immunisation.

<div style=\"page-break-after: always\"></div>

Pharmacokinetic studies have not been performed and are generally not required for tumour immunotherapy products or adjuvants in accordance with the Guideline on the evaluation of anticancer medicinal products in man Rev. 4'.

The product applied for holds an autologous Id-antigen conjugated to the KLH adjuvant specifically produced for every individual patient. Thus, every batch will be different in terms of the antigenic amino acid sequence. Therefore, conventional toxicology studies are neither appropriate nor relevant.

To use homologues murine Id-antigens for toxicity testing could potentially have provided data on the safety profile of the product (local tolerance, systemic effects), however such data could also be questioned due to the autologous nature of the human product. Nevertheless, taking the general safety profile of tumour immunotherapy products and the available clinical data in to account, it is concluded that additional animal toxicology studies are not required.

As to the carrier protein, KLH, the applicant did not include any discussion or data on its toxicological properties,  but  rely  on  clinical  data  to  substantiate  safety.    GM-CSF  has  been  used  in  the  past extensively in the clinic. Thus, from a non-clinical point of view additional non-clinical toxicology studies with GM-CSF are not required.

Environmental risk assessment has not been submitted in accordance with the guidance on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) which  specifically  exempts  amino  acids,  peptide  and  proteins  from  the  need  for  a  detailed environmental assessment.

## 2.4. Conclusion on the non-clinical aspects

Overall, the non-clinical overview of the published literature was considered adequate.

## 2.5. Clinical aspects

## 2.5.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 2: Overview of clinical studies

<!-- image -->

## 2.5.2. Pharmacokinetics

No pharmacokinetic studies have been submitted.

## 2.5.3. Pharmacodynamics

The pharmacodynamics of Lympreva has been studied in relation to the following clinical studies: a phase 2 clinical study in patients with advanced-stage follicular NHL in first complete remission (CR)

<div style=\"page-break-after: always\"></div>

(NCI T93-0164), and a phase 2 bridging study in mantle cell lymphoma (MCL) patients in first remission achieved with a rituximab combination chemotherapy induction regimen (NCI 1033).

## Mechanism of action

No clinical pharmacodynamic studies were submitted.

## Primary and Secondary pharmacology

The primary pharmacology has been studied using various biomarkers of immune response. The immune  response  endpoints  investigated  in  these  studies  include:  Humoral  anti-Id  response, Proliferative anti-Id response, Increase in tumour specific cytolytic T-lymphocytes precursors (CTLp) frequency,  Tumour-specific  direct  cytotoxicity,  Tumour-specific  cytokine  production,  Id-specific cytokine production.

In both studies 5 immunizations were administered at month 1, 2, 3, 4, and 6. Each immunization consisted of subcutaneous injections administered over 4 days: (Id-KLH with GM-CSF on Day 1 and GM-CSF on Days 2-4). The dose of Id-KLH was 0.5 mg Id conjugated to 0.5 mg KLH and administered subcutaneously on day 1. Immune responses were available for 20/42 enrolled patients in study NCI T93-0164  and  for  23/26  enrolled  patients  in  study  NCI  1033.  The  pharmacodynamic  biomarker responses are summarized in Table 3.

Table 3: Immune response data from 2 phase 2 studies

| Critical Aspects of Study Design and Endpoints   | NCI T93-0164 (Bendandi 1999)                                                                                                                                                      | NCI1033 (Neelapu 2005; Grant 2011; Dunleavy 2012)                                                                                                                                                                                      |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study population (N/ histology/ prior therapy)   | 20/ FL/ Treatment naive                                                                                                                                                           | 23/ MCL/ Treatment naive                                                                                                                                                                                                               |
| Vaccine adjuvant                                 | GM-CSF 100 μg/m2/day vs. 500 μg/m2/day                                                                                                                                            | GM-CSF 100 μg/m2/day                                                                                                                                                                                                                   |
| Vaccine schedule (month)                         | 0, 1,2,3,5                                                                                                                                                                        | 0, 1,2,3,5                                                                                                                                                                                                                             |
| Vaccine dose                                     | 0.5 mg Id conjugated to 0.5 mg KLH                                                                                                                                                | 0.5 mg Id conjugated to 0.5 mg KLH                                                                                                                                                                                                     |
| Time to vaccine (months)                         | 12.3 to 17.7                                                                                                                                                                      | 2.1 to 8.3                                                                                                                                                                                                                             |
| Disease status at vaccine                        | 20 CR                                                                                                                                                                             | 22 CR 1 PD                                                                                                                                                                                                                             |
| Anti-Id Ab (N/ 96)                               | 15 (75)                                                                                                                                                                           | 7(30)                                                                                                                                                                                                                                  |
| Anti-Id Ab kinetics                              | ND                                                                                                                                                                                | Detected after 4th-5th vaccine (concomitant to post-rituximab B-cell recovery)                                                                                                                                                         |
| Tumor-specific cytokine release                  | 19 (95%%) patients Duration 6+to 18+months TNFα: median 825 pg/mL; range 92- 2,453 Pg/mL INFy: median 121 pg/mL; range 50-290 pg/mL GM-CSF: median 112 pg/mL; range 53- 372 Pg/mL | 20 (87) patients Detected after 3\"vaccine (concomitant to total B-cell depletion post- rituximab) TNFo: median 1.65 pg/mL; range 0-37.8 pg/mL INFy: median 4.75 pg/mL; range 0-63.1 pg/mL GM-CSF: median 4.3 pg/mL; range 0-56.3 pg/mL |
| Id-specific cytokine release (N/ (96             | ND                                                                                                                                                                                | 13(57)                                                                                                                                                                                                                                 |
| Iumor-specific direct cytotoxicity               | Substantial tumor-specific lysis of autologous FL targets mediated by post-immune CD8+ T-cells                                                                                    | Tested in 1 patient: 2796 post-vaccine tumor-specific lysis compared to 2% for pre-vaccine                                                                                                                                             |
| T-rell precursor frequency (N/ (96               | ND                                                                                                                                                                                | 9 (39) patients had significant increase in frequency post-vaccine compared to pre-vaccine                                                                                                                                             |

In the study of patients not receiving rituximab, immune responses were available for 20/42 enrolled patients. CD4+ and CD8+ cytokine were induced in 19/20 patients while humoral Id-responses demonstrated in 15/20 of patients; in the study with patients pre-treated with rituximab, CD4+ and

<div style=\"page-break-after: always\"></div>

CD8+ cytokine responses were induced in 87% of the treated patients, while humoral Id-responses were demonstrated in 30% of the patients.

## 2.5.4. Discussion on clinical pharmacology

The pharmacodynamics of Lympreva has been investigated in two clinical studies by assessment of various biomarkers of immune response.

## 2.5.5. Conclusions on clinical pharmacology

Additional clinical pharmacology studies for Lympreva are not required.

## 2.6. Clinical efficacy

## 2.6.1. Dose response studies

No dose/response studies were performed.

## 2.6.2. Main study

## Study BV301

## Methods

Study  BV301  was  a  a  phase  3,  double-blind,  controlled, multicenter randomized  trial of patient-specific  active  immunisation  with  Lympreva  (an  autologous  immunoglobulin  follicular lymphoma idiotype immunotherapy fused with KLH) with local GM-CSF in first complete remission, compared to  a  control  consisted  only  of  carrier  (KLH)  and  adjuvant  (GM-CSF),  in  patients  with indolent, Stage IIx, III, or IV follicular lymphoma (FL) in first CR/CRu (CR unconfirmed) achieved with PACE (prednisone, doxorubicin, cyclophosphamide, and etoposide).

## Study Participants

## Inclusion criteria

Patients had to meet the following criteria:

1. Tissue diagnosis of FL with surface IgM or IgG phenotype with a monoclonal heavy and light chain as determined by flow cytometry.. The histology of the lymph node biopsy as evaluated by the NCI should be Follicular Center Cell (FCC) Grade I, II, or IIIa (FSC lymphoma, FM, or follicular large cell lymphoma with centrocytes).

2. Stage II with bulky adenopathy (&gt; 5 cm in diameter), Stage III or IV lymphoma.
3. Patients should be chemotherapy naive-patients and may have received prednisone (&lt;2 months of therapy).
4. Previous treatment with radiation alone (\u0014 2 sites) was permissible.

5. A single peripheral lymph node &gt; 2 cm size accessible for biopsy/harvest or an abdominal lymph node &gt; 2 cm that was accessible for laparoscopic biopsy. Patients with lymphoma cells circulating in the peripheral blood, malignant pleural effusions, or malignant ascites may have been eligible if adequate lymphoma cells were present (&gt; 109).

<div style=\"page-break-after: always\"></div>

6. ECOG performance status &lt; 2, unless the performance was directly related to disease and therefore should have improved with therapy.
7. Life expectancy of &gt; 1 year.
8. Serum creatinine &lt; 1.5 mg/dl unless secondary to lymphoma.
9. Bilirubin ≤ 1.5 mg/dl unless secondary to lymphoma or Gilbert's disease. SGOT/SGPT &lt; 3.5 x upper limit of normal.
10. Ability to give informed consent. Ability to return to clinic for adequate follow-up for the period that the protocol requires.

## Exclusion criteria

Any patient who met any of the following criteria was excluded:

1. Any amount of radiation exceeding 2 sites, including prior total body irradiation (TBI).
2. Presence of antibodies to human immunodeficiency virus (HIV), hepatitis B surface antigen or other active infectious process.
3. Pregnancy or lactation.
4. A history of unrelated (non-lymphomatous) neoplasm within the past 10 years other than non-melanoma skin cancer or in-situ cervix cancer. Patients with a prior diagnosis of malignancy more than 10 years may have entered into the study at the discretion of the PI.
5. Unwilling to give informed consent.
6. Failure to meet any of the eligibility criteria.
7. Any medical or psychiatric condition that, in the opinion of the protocol chairman, would compromise the patient's ability to tolerate this treatment.
8. Patient with primary or secondary central nervous system (CNS) lymphoma (current or previously treated) was not eligible.

## Treatments

Segment A: Within 30 days of the date of Segment A registration, patients were to receive induction chemotherapy with PACE (Prednisone, Doxyrubicin, Cyclophosphamide, and Etoposide) until they achieved their best response. Each complete responder was to have received a minimum of 6 cycles before therapy was discontinued. Patients who achieved a CR/CRu were to enter on the vaccination part of the protocol and randomized. Patients with less than a CR/CRu or with PD were to be taken off of the study. Only 8 cycles of chemotherapy with adriamycin and 10 total cycles of chemotherapy were allowed.

The dose and schedule for each PACE chemotherapy 28-day cycle are described in Table 4.

Table 4: PACE chemotherapy doses and schedule per cycle (Study BV301)

<!-- image -->

| Day1                                          | Day8                                          | Day14   | Day 29               |
|-----------------------------------------------|-----------------------------------------------|---------|----------------------|
| Cyclophosphamide650mg/m                       | Cyclophosphamide650mg/m²                      |         | Start of next cyclea |
| Doxorubicin25mg/m                             | Doxorubicin25mg/m                             |         | Start of next cyclea |
| EtoposideVP-16120mg/m²                        | EtoposideVP-16120mg/m²                        |         | Start of next cyclea |
| Prednisone40 mg/m²,daily x14（i.e.,Days1 to14) | Prednisone40 mg/m²,daily x14（i.e.,Days1 to14) |         | Start of next cyclea |

\"At least6 cycles were administered.

Segment B :Six months (up to a maximum period of 12 months) after the completion of induction chemotherapy, all patients who had not relapsed were randomized and planned to receive a series of

<div style=\"page-break-after: always\"></div>

5 subcutaneous injections at 1, 2, 3, 4 and 6 months according to doses described in Table 5, as shown in Figure 1.

Table 5: Vaccination Therapy Schedule and Doses (Study BV301)

<!-- image -->

| Group   | Day 1                            | Day2                | Day3                 | Day4                |
|---------|----------------------------------|---------------------|----------------------|---------------------|
| Active  | 1mgIdKLH 100pg/m/dayGM-CSF       | 100 μg/m/day GM-CSF | 100 pg/m7/day GM-CSF | 100 μg/m/day GM-CSF |
| Conirol | Imgk KLH-KLH 100 μg/m/day GM-CSF | 100 μg/m7day GM-CSF | 100 pg/m7day GM-CSF  | 100 μg/m/day GM-CSF |

Figure 1: Design of Study BV301

<!-- image -->

## Objectives

The primary objective was to evaluate efficacy  and safety by assessing significant prolongation of clinical Disease-Free Survival (DFS) following Lympreva + GM-CSF when compared to DFS following administration of KLH + GM-CSF, in FL patients achieving a CR with standard dose chemotherapy.

Secondary objectives included the following: to determine the ability of Id-vaccine to produce a molecular CR in patients in clinical CR, but with PCR evidence of residual disease after standard chemotherapy; to determine the impact of Id immunization on molecular DFS in FL patients; to evaluate the ability of Id vaccine to generate an immunology response against autologous tumour; to determine and compare the overall survival of patients randomized to receive either treatment arm; to evaluate the safety of a series of 5 immunization injections administered with GM-CSF as adjunct therapy over a 6 month period.

## Outcomes/endpoints

The primary endpoint was the clinical Disease-Free Survival, defined as duration from randomization to relapse or last follow-up.

<div style=\"page-break-after: always\"></div>

Secondary endpoints included the following:

Molecular CR (defined as the proportion of patients achieving a molecular CR (CR + PCR negative) after  vaccination  among  those  with  a    CR/CRu  and  PCR  evidence  of  residual  disease  before vaccination);

Molecular DFS defined as the duration of molecular DFS after randomization in FL patients achieving a CR but with PCR evidence of residual disease before vaccination;

Rate of immune response against the autologous tumour; defined as the proportion of patients who achieve an immunologic response against the autologous tumour;

Overall survival defined as the time from randomization to the date of death due to any reason or last follow-up.

## Sample size

The following assumptions are used to estimate the sample size of the study:

·  85% of patients entered onto the trial and administered PACE chemotherapy are expected to achieve a complete remission (CR) or CRu. Updated enrollment data from the clinical trial suggest that the actual proportion of patients achieving CR/CRu from PACE chemotherapy is higher than originally assumed (i.e. 80 - 85% vs. 66% as described in protocol version P).

· 87% of patients entered onto the trial and administered CHOP-R chemotherapy are expected to achieve a complete remission (CR) or CRu.

· CHOP-R was not used in the first years of accrual and it is currently assumed for power calculation purposes that a fixed proportion of patients entered onto the trial will use CHOP-R in the later 2 years of the recruitment period (75%).

· The median disease-free survival for patients with follicular lymphoma treated with GM-CSF alone after PACE chemotherapy is expected to be 3.5 years.

· The median disease-free survival for patients with follicular lymphoma treated with GM-CSF alone after CHOP-R chemotherapy is expected to be 6.9 years.

·  This  study  will  utilize  an  intent-to-treat  design  and  all  patients  will  be  analyzed  as  they  were randomized.

·  Sample  size  calculations  will  be  performed  based  on  simulations  assuming  an  intent-to-treat analysis, equal hazards (1.0 hazard ratio) for the first 8 months (when treatments are expected to be the same in both randomized arms), and then a hazard ratio of 2.0 after 8 months.

• A two-sided hypothesis test at the alpha=0.01 level will be used to ensure a stringent evaluation.

· A 2:1 randomization favoring Id-KLH vaccine will be used to gain more information about the effects of vaccine in this group of patients.

Based  on  the  above,  563  patients  were  planned  to  be  enrolled  and  receive  PACE  as  first  line chemotherapy treatment (Segment A) so that 375 patients (Segment B) could be randomized at a 2:1 rate to the vaccine (Lympreva+GM-CSF) arm (n=250) or to the control (KLH-KLH+GM+CSF) arm (n=125).

However,  during  the  08  April  2008  DMC  meeting,  it  was  recommended  that  enrollment  be discontinued before reaching the intended sample size.

## Randomisation

Patients were randomised immediately after completion of chemotherapy to be allocated to active or control  arm  with  a  ratio  of  2:1,  respectively.  Randomization  was  stratified  by  number  of

<div style=\"page-break-after: always\"></div>

chemotherapy cycles (&lt;8 vs. ≥8), and IPI (International Prognostic Index) risk group (levels 0, 1 and 2 vs. levels 3 and 4).

## Blinding (masking)

This was a double-blinded study.

## Statistical methods

A 2-sided test was planned at a Type I error rate of 0.01 for the primary efficacy analysis of this study. All other statistical analyses were to be performed using a 2-sided hypothesis test at the overall 5% level of significance and a 95% confidence interval (CI). No adjustment for Type I error was planned for multiple comparisons if applicable. Since there were no multiple comparisons planned in this study, adjustments for multiple comparisons were not made. A row denoted \"Missing\" was included in count tabulations where necessary to account for dropouts and missing values. The denominator for all percentages was the number of patients in that treatment within the population of interest. Missing data were not imputed.

Patients who received additional chemotherapy and/or radiation therapy after randomization were considered to be off-study and did not receive the vaccine. Patients who relapsed after randomization but prior to vaccination did not receive the vaccine but were included in the intent-to-treat (ITT) population as censored observations and were followed for survival. Patients randomized to receive the Lympreva for whom the Lympreva could not be made received the KLH control vaccine and were analyzed according to the study arm they were randomized.

The population used for the primary analyses include patients that underwent vaccination (patients who achieved CR/CRu after induction with PACE and underwent randomisation between active and control vaccination.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

## Recruitment

The trial was conducted from 14 January 2000 (first patient enrolled) to 16 October 2007 (last patient completed). A total of 17 centres in US, Russia and Ukraine were involved.

## Conduct of the study

Major protocol deviations and violations are reported in Table 6.

<div style=\"page-break-after: always\"></div>

Table 6: Major Protocol Deviations and Violations (ITT Population, Study BV301)

| MajorProtocol Dcvlatlons             |    |      |
|--------------------------------------|----|------|
| AssessmentDevialions                 | 32 | 18.1 |
| Deviation Other.Minor                | 12 | 6.8  |
| MajorProtocolVlolatlons              |    |      |
| Dosing Violations                    |    | 2.3  |
| InclusionExclusionCnileriaViolations |    | 0.6  |
| OiherViolations                      | 14 | 7.9  |

IT'T population includes all patients who were randomized to one of the treatment amms, as randomized. Percenlage indicates number of patients with a prolocol deviation or violation from the ITT population.

A total of 19 amendments were made to the protocol between 02 August 2000 and 14 March 2007. The major ones are summarised below.

Amendment 3 (14 July 2001) included an update to provide a more stringent evaluation of the primary efficacy endpoint and generate a more robust outcome as follows: a 2-sided hypothesis test at the alpha=0.01 level was implemented; the sample size was increased from 450 to 563 total enrolled patients; patients randomized to the Id-KLH arm for whom vaccine could not be made were to receive KLH control and be analyzed as randomized. Overall survival was added as a secondary endpoint. A provision was added to clarify that only patients who maintained their CR/CRu would receive  vaccinations.  It  was  also  specified  that  vaccination  therapy  must  be  administered  at  a Consortium site, and that only randomized patients who had relapsed would receive vaccinations.

Amendment 5 (24 July 2001) expanded the eligibility criteria to include patients with Stage II with bulky adenopathy, and patients with tumour histology of FL Grade IIIa.

Amendment  8  (22  April  2003)  included  changes  regarding  the  following:  additional  sources  of lymphoma  cells  for  vaccine  production  (i.e.,  peripheral  blood,  pleural  effusion,  and  ascites); additional methods of tissue procurement (i.e., mini-laparotomy for abdominal nodes not accessible via biopsy), a clarification of relapse criteria using tissue diagnosis.

Amendment 10 (03 December 2003): PACE chemotherapy modifications included a Prednisone dose reduction from 60 mc/m 2  to 40 mg/m 2 , and the specification that dexamethasone use while on PACE regimen was not permitted.

Amendment M (10 May 2004) was the first amendment after the IND transfer from NCI to Biovest, and reflected the changed responsibilities, administrative changes in study conduct, and removal of irrelevant information.

Amendment R (no version date) changed the expected CR/CRu rate from PACE chemotherapy from 66% to 80-85% based on the observed response rate in the patients enrolled in the study, which resulted in a sample size reduction from 563 to 460.

Amendment T (14 March 2007): addition of the CHOP-R regimen as an induction therapy. The choice of induction therapy regimen was at the discretion of the PI or the treating physician. In addition to the changes driven by the CHOP-R addition, several protocol changes were included as follows: the requirement to collect bone marrow aspirates for molecular analyses was removed throughout as their value was reassessed as less reliable than that of peripheral blood samples; added requirement for collection of peripheral blood for T-cell assays and serum and peripheral blood for storage; the requirement for chest X-rays during the screening visits was removed; the option for Fine Needle aspiration (FNA) for relapsed disease determination was removed. Ten patients were enrolled under Amendment T.

<div style=\"page-break-after: always\"></div>

## Baseline data

Baseline demographic and disease characteristics are summarized in Table 7.

Table 7. Demographics and Baseline Characteristics (ITT Population, Study BV301)

|                                       | Active (N=118)   | Active (N=118)   | Control (N=59)   | Control (N=59)   | All Patlents (N=177)   | All Patlents (N=177)   |       |
|---------------------------------------|------------------|------------------|------------------|------------------|------------------------|------------------------|-------|
| Characterlstlc                        | N                | %                | N                | %                | N                      | %                      | pt    |
| Gender                                |                  |                  |                  |                  |                        |                        | 0.338 |
| Male                                  | 60               | 50.8             | 35               | 59.3             | 95                     | 53.7                   |       |
| Female                                | 58               | 49.2             |                  | 40.7             | 82                     | 46.3                   |       |
| Age                                   |                  |                  |                  |                  |                        |                        | 0.586 |
| Me an (SD)                            | 49.7 (9.9)       | 49.7 (9.9)       | 50.1 (9.8)       | 50.1 (9.8)       | 49.8 (9.9)             | 49.8 (9.9)             |       |
| Median                                | 49.7             | 49.7             | 50.0             | 50.0             | 49.9                   | 49.9                   |       |
| Min, Max                              | 19.2, 80.1       | 19.2, 80.1       | 30.2,69.2        | 30.2,69.2        | 19.2, 80.1             | 19.2, 80.1             |       |
| Age category                          |                  |                  |                  |                  |                        |                        | 0.861 |
| <50 years                             | 60               | 50.8             | 30               | 50.8             | 90                     | 50.8                   |       |
| 50-59 years                           |                  | 33.9             | 19               | 32.2             | 59                     | 33.3                   |       |
| 60-69 years                           | 15               | 12.7             | 10               | 16.9             | 25                     | 14.1                   |       |
| 70-79 years                           | 2                | 1.7              | 0                | 0'0              | 2                      | 1. 1                   |       |
| ≥80 years                             | 1                | 0.8              | 0                | 0.0              | 1                      | 0.6                    |       |
| Race/Ethniclty                        |                  |                  |                  |                  |                        |                        | 0.797 |
| White                                 | t01              | 88.1             | 52               | 88.1             | 156                    | 88.1                   |       |
| Black                                 | 5                | 4.2              | 5                | 8.5              | 10                     | 5.6                    |       |
| Hispanic or Latino                    |                  | 3.4              | 1                | 1.7              | 5                      | 2.8                    |       |
| Asian                                 |                  | 3.4              | 0                | 0.0              |                        | 2.3                    |       |
| American Indian or                    | 1                | 0.8              | 0                | 0.0              | 1                      | 0.6                    |       |
| Alaskan Native                        |                  |                  |                  |                  |                        |                        | 0.219 |
| Other                                 | 0                | 0.0              | 1                | 1.7              | 1                      | 0.6                    |       |
| Stage at study enrollment             |                  |                  |                  |                  |                        |                        |       |
| Stage II                              | 2                | 1.7              | 1                | 1.7              | 3                      | 1.7                    |       |
| Stage III                             | 40               | 33.9             | 13               | 22.0             | 53                     | 29.9                   |       |
| Stage IV                              | 76               | 64.4             | 45               | 76.3             | 121                    | '89                    |       |
| Histology                             |                  |                  |                  |                  |                        |                        | 0.749 |
| Follicular Mixed                      | 9                | 54.2             | 34               | 57.6             | 86                     | 55.4                   |       |
| Lymphoma                              |                  |                  |                  |                  |                        |                        |       |
| Follicular Small Cleaved              | 54               |                  | 25               | 42.4             | 79                     | 44.6                   |       |
| Cell Lymphoma ECOG Performance Status |                  |                  |                  |                  |                        |                        | 1.000 |
| 0                                     | t6               | 79.7             | 46               | 78.0             | 140                    | 79.1                   |       |
| 1                                     | 23               | 19.5             | 12               | 20.3             | 35                     | 19.8                   |       |
| 2                                     | 1                | 0.8              | 1                | 1.7              | 2                      | 1.1                    |       |

<div style=\"page-break-after: always\"></div>

| FLIPI risk group Low Risk (0,1)   | 65                            | 55.1   | 87   | 47.5   | 93   | 52.5   | 0.559   |
|-----------------------------------|-------------------------------|--------|------|--------|------|--------|---------|
| Intermediate Risk (2)             | 39                            | 33.1   | 22   | 37.3   | 61   | 34.5   |         |
| High Risk (3,4,5)                 | 13                            | 11.0   | 9    | 15.3   | 22   | 12.4   |         |
| Missing                           |                               | 0.8    | 0    |        | 1    |        |         |
|                                   |                               |        |      | 0.0    |      | 0.6    |         |
| IPI risk group                    |                               |        |      |        |      |        | 1.000   |
| Low or Low-Intermediate (0,1,2)   | 105                           | 89.0   | 53   | 89.8   | 158  | 89.3   |         |
| High-Intermediate or High (3,4,5) | 13                            | 11.0   | 6    | 10.2   | 19   | 10.7   |         |
| Tumor Isotype                     |                               |        |      |        |      |        | 0.360   |
| IgD                               | 1                             | 0.8    | 1    | 1.7    | 2    | 1. 1   |         |
| IgG                               | 55                            | 46.6   | 23   | 39.0   | 78   | 44.1   |         |
| IgM                               | 61                            | 51.7   | 33   | 55.9   | 6    | 53.1   |         |
| IgM/IgG                           | I                             | 0.8    | 2    |        | 3    | 1.7    |         |
| Number of chemotherapy cycles     | Number of chemotherapy cycles |        |      |        |      |        | 1.000   |
| 8                                 | 60                            | 50.8   | 29   | 49.2   | 89   | 50.3   |         |
| ≥8                                | 58                            | 49.2   | 30   | 50.8   | 88   | 49.7   |         |

ECOG = Eastem Cooperative Oncology Group: IPI= International Prognostic Index; FLIPI = Follicular

Lymphoma Intemational Prognostic Index: Ig = Immunoglobulin

Comparison performed with two-sided Fisher Exact Test for categorical variables; otherw ise, a Wilcoxon Rank Sum Test for mean level comparisons.

Active = dasiprotimut-T Biovest + GM-CSF; Control = KLH-KLH + GM-CSF

ITT population includes all patients who were randomized to one of the treatment arms, as randomized.

## Numbers analysed

Patient populations of the Study BV301 are reported in Table 8.

Table 8: Patient Population Definition and Enrollment (Study BV301)

| Population        | Definilion                                                                                                                                                                                                          | Total Number in Defined Population   | Enrollment per Treatment group Active/ Conlrol   |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------|
| All Enrolled      | All patients screened and enrolled in Segment A. Patients scrcened and pre-registered for lymph node biopsy wcre not included.                                                                                      | N= 234                               | NA                                               |
| ITT Population    | All paticnts who were randomized to one of the trcalmcnt groups (in Segmcnt B) - regardless of whether or not they reccived study drug - and analyzed nccording to the treatment assigncd.                          | N= 177                               | 118t/59                                          |
| PP Population     | Allputicnts randomizcd to onc of the treatment groups, cxcluding those with major protocol violations and for whom vaccine could be mnde. and analyzcd aocording to the trenlmicnt reoeived.                        | N= 97                                | 62/35                                            |
| Safety Population | All patients cxposcd to trcatmcnt (in Segmcnt B)  iLc, rcccivcd at least on dosc of study drug (eithcr active [Dasiprotimut-T+GM-CSF]or control [KLH-KLH+GM-CSF]) and analyzed according to the trealment reccived. | N= 117                               | 71/46t                                           |

Active =Dasiprolimut-T Biovest+GM-CSF; Control = KLH-KLH+GM-CSF; GM-CSF= granulocyte macrophage colony-stimulating factor; KLH = keyhole limpet haemocyanin

t Includes 5 patients randomized to vaccine but reccived control

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint: Disease-free Survival

In the ITT population, results in term of median DFS are shown in Table 9 and Figure 2. Patients who relapsed prior to receiving vaccine were treated as censored observations.

Table 9: Duration of Clinical Disease-Free Survival Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles, censoring untreated patients (ITT Population, Study BV301)

|                                               | Active (N=118)   | Control (N=59)   | P-value   |
|-----------------------------------------------|------------------|------------------|-----------|
| Log-rank test                                 |                  |                  | 0.029     |
| Median, months                                | 46.0             | 30.6             |           |
| 95% CI                                        | 36.2-63.9        | 26.2-39.8        |           |
| Length of follow-up: min-max (median, months) | 4.2-92.0 (55.2)  | 5.7-90.7 (56.6)  |           |
| Number of events                              | 43               | 29               |           |
| Number censored                               | 75               | 30               |           |

Active = dasiprotimut-T Biovest + GM-CSF; Control = KLH-KLH + GM-CSF

Figure 2: Kaplan-Meier Estimation of Clinical Disease-Free Survival Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles, censoring untreated patients (ITT Population, Study BV301)

<!-- image -->

Median DFS results when all events occurring after randomization are counted are reported in Table 10 and Figure 3.

Table 10: Duration of Clinical Disease-Free Survival Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles, Untreated Patients as Events (ITT Population, Study BV301)

<div style=\"page-break-after: always\"></div>

|                                           | Active (N=118)   | Control (N=59)   | P-value   |
|-------------------------------------------|------------------|------------------|-----------|
| Log-ranktest                              |                  |                  | 0.295     |
| Median.months                             | 20.1             | 20.6             |           |
| 95%CI                                     | 15.0-35.1        | 14.5-30.6        |           |
| Lengthoffollow-up:min-max (median,months) | 4.2-92.0 (55.2)  | 5.7-90.7 (56.6)  |           |
| Numberofevents                            | 85               | 47               |           |
| Numbercensored                            | 33               | 12               |           |

Figure 3: Kaplan-Meier Estimation of Clinical Disease-Free Survival Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles, Untreated Patients as Events (ITT Population, Study BV301)

<!-- image -->

## Secondary key endpoint: Overall Survival

In the ITT population, because the follow-up duration of the study is not long enough median OS was not reached in either treatment arm (data not shown).

## Ancillary analyses

Subgroup analyses for DFS (censoring events occurring before vaccination) are shown in Figure 4.

<div style=\"page-break-after: always\"></div>

Figure 4: Forest Plot of DFS by Subgroups (ITT Population, Study BV301)

<!-- image -->

Duration of Clinical DFS in IgM Patients with untreated patients as events and censoring patients that did not receive the study drug is reported in Table 11 and Table 12, respectively.

Table 11: Duration of Clinical Disease-Free Survival in IgM Patients, Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles with Untreated Patients as Events (ITT Population, Study BV301)

|                                           | Active (N=61)   | Control (N=33)   | P-value   |
|-------------------------------------------|-----------------|------------------|-----------|
| Log-ranktest                              |                 |                  | 0.366     |
| Median,months                             | 16.6            | 21.0             |           |
| 95%CI                                     | 12.4-46.0       | 16.2-32.2        |           |
| Lengthoffollow-up:min-max (median,months) | 4.2-87.1 (55.0) | 5.7-90.7 (53.4)  |           |
| Numberofevents                            | 43              | 28               |           |
| Numbercensored                            | 18              | 5                |           |

Active=Dasiprotimut-TBiovest+GM-CSF;Control=KLH-KLH+GM-CSF

<div style=\"page-break-after: always\"></div>

Table 12: Duration of Clinical Disease-Free Survival in IgM Patients, Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles censoring untreated patients (ITT Population, Study BV301)

|                                           | Active (N=61)   | Control (N=33)   | P-value   |
|-------------------------------------------|-----------------|------------------|-----------|
| Log-ranktest                              |                 |                  | 0.004     |
| Median,months                             | 52.9            | 28.7             |           |
| 95%CI                                     | 40.2-NR         | 21.0-39.8        |           |
| Lengthoffollow-up:min-max (median,months) | 4.2-87.1 (55.0) | 5.7-90.7 (53.4)  |           |
| Numberofevents                            | 17              | 20               |           |
| Numbercensored                            | 44              | 13               |           |

Active=Dasiprotimut-TBiovest+GM-CSF;Control=KLH-KLH+GM-CSF NR=NotReached

## FLIPI Risk Groups

DFS within FLIPI groups with untreated patients as events and censoring patients that did not receive the study drug is reported in Table 13 and Table 14, respectively.

Table 13: Duration of Clinical Disease-Free Survival within FLIPI Risk Groups Counting Untreated Patients as Events (ITT Population, N= 177 - Study BV301)

|                                            | Active (N=117)   | Control (N=59)   | P-value   |
|--------------------------------------------|------------------|------------------|-----------|
| OverallLog-ranktest                        |                  |                  | 0.394     |
| High (3,4,5)                               |                  |                  |           |
| Log-rank test                              |                  |                  | 0.904     |
| Median,months                              | 19.9             | 20.6             |           |
| I0%S6                                      | 5.7-NR           | 15.6-NR          |           |
| Lengthoffollow-up:min-max (median,months)  | 4.2-88.1 (57.5)  | 27.3-81.9 (59.3) |           |
| Number ofevents                            | 10               | 8                |           |
| Number censored                            | 3                | 1                |           |
| Intermediate (2)                           |                  |                  |           |
| Log-rank test                              |                  |                  | 0.887     |
| Median,months                              | 14.9             | 8.8              |           |
| 95%CI                                      | 8.4-33.2         | 7.6-27.6         |           |
| Lengthoffollow-up:min-max (median,months)  | 7.4-87.1 (50.2)  | 5.7-86.7 (56.6)  |           |
| Number ofevents                            | 31               | 17               |           |
| Number censored                            | 8                | 5                |           |
| Low (0,1)                                  |                  |                  |           |
| Log-rank test                              |                  |                  | 0.292     |
| Median,months                              | 28.3             | 27.1             |           |
| 95%CI                                      | 17.3-50.2        | 19.7-39.8        |           |
| Lengthoffollow-up:min-max (median, months) | 7.5-92.0 (58.2)  | 9.7-90.7 (57.1)  |           |
| Number ofevents                            | 43               | 22               |           |
| Number censored                            | 22               | 6                |           |

<div style=\"page-break-after: always\"></div>

Table 14: Duration of Clinical Disease-Free Survival within FLIPI Risk Groups censoring untreated Patients (ITT Population, N= 177 - Study BV301)

|                                              | Active (N=117)   | Control (N=59)   | P-value   |
|----------------------------------------------|------------------|------------------|-----------|
| Overall Log-rank test                        |                  |                  | 0.042     |
| High (3,4,5)                                 |                  |                  |           |
| Log-rank test                                |                  |                  | 0.204     |
| Median,months I0%S6                          | 52.9 20.1-NR     | 30.6 16.2-NR     |           |
| Lengthoffollow-up:min-max (median, months)   | 4.2-88.1 (57.5)  | 27.3-81.9 (59.3) |           |
| Numberof events                              | 4                | 6                |           |
| Number censored                              | 9                | 3                |           |
| Internediate (2)                             |                  |                  |           |
| Log-ranl test                                |                  |                  | 0.849     |
| Median,months                                | 36.2             | 27.6             |           |
| I0%56                                        | 21.7-NR          | 21.0-NR          |           |
| Length of follow-up:min-max (median, months) | 7.4-87.1 (50.2)  | 5.7-86.7 (56.6)  |           |
| Number ofevents                              | 14               | 6                |           |
| Numbercensored                               | 25               | 16               |           |
| Low (0.1)                                    |                  |                  |           |
| Log-rank test                                |                  |                  | 0.026     |
| Median,months 95%CI                          | 50.2 37.9-NR     | 32.1 26.2-42.7   |           |
| Length of follow-up: min-max                 | 7.5-92.0 (58.2)  | 9.7-90.7 (57.1)  |           |
| (median,months) Nuumberof events             | 24               | 17               |           |
| Number censored                              | 41               | 11               |           |

## Gender

Results in terms of DFS within gender when counting patients not receiving active study drug as events and when the untreated patients are censored are summarized in Table 15 and Table 16, respectively.

<div style=\"page-break-after: always\"></div>

Table 15: Duration of Clinical Disease-Free Survival with Untreated Patients as Events within Gender (ITT Population, N= 177- Study BV301)

|                                            | Active (N=118)   | Control (N=59)   | P-value   |
|--------------------------------------------|------------------|------------------|-----------|
| OverallLog-ranktest                        |                  |                  | 0.416     |
| Female                                     |                  |                  |           |
| Log-rank test                              |                  |                  | 0.056     |
| Median,months                              | 20.8             | 15.0             |           |
| 95%CI                                      | 12.6-52.9        | 9.4-27.1         |           |
| Lengthoffollow-up:min-max                  | 7.4-87.1 (54.9)  | 9.7-90.7 (57.1)  |           |
| (median,months)                            |                  |                  |           |
| Numberofevents                             | 38               | 21               |           |
| Number censored                            | 20               | 3                |           |
| Male                                       |                  |                  |           |
| Log-rank test                              |                  |                  | 0.634     |
| Median,months                              | 20.1             | 27.6             |           |
| I0%56                                      | 14.9-36.2        | 20.0-39.8        |           |
| Length offollow-up:min-max (median,months) | 4.2-92.0 (56.2)  | 5.7-86.7 (54.6)  |           |
| Numberofevents                             | 47               | 26               |           |
| Numbercensored                             | 13               | 9                |           |

Active=Dasiprotimut-TBiovest+GM-CSF;Control=KLH-KLH+GM-CSF

NR=NotReached

Table 16: Duration of Clinical Disease-Free Survival within Gender (ITT Population, N= 177- Study BV301)

|                           | Active (N=118)   | Control (N=59)   | P-value   |
|---------------------------|------------------|------------------|-----------|
| OverallLog-ranktest       |                  |                  | 0.110     |
| Female                    |                  |                  |           |
| Log-rank test             |                  |                  | 0.032     |
| Median,months             | 63.9             | 27.1             |           |
| I0%56                     | 44.2-NR          | 19.7-NR          |           |
| Lengthoffollow-up:min-max | 7.4-87.1 (54.9)  | 9.7-90.7 (57.1)  |           |
| (median,months)           |                  |                  |           |
| Numberofevents            | 17               | 10               |           |
| Numbercensored            | 41               | 14               |           |
| Male                      |                  |                  |           |
| Log-rank test             |                  |                  | 0.598     |
| Median,months             | 37.9             | 32.4             |           |
| 95%CI                     | 26.7-59.4        | 26.7-42.7        |           |
| Lengthoffollow-up:min-max | 4.2-92.0 (56.2)  | 5.7-86.7 (54.6)  |           |
| (median,months)           |                  |                  |           |
| Number ofevents           | 26               | 19               |           |
| Numbercensored            | 34               | 16               |           |

Active=Dasiprotimut-T Biovest+GM-CSF;Control=KLH-KLH+GM-CSF NR=NotReached

<div style=\"page-break-after: always\"></div>

An additional alternative analysis of DFS was submitted. This analysis of DFS considers the time that the vaccine became available as Time 0.

Table 17 provides the summary of DFS analysis that excludes pre-study treatment time. Figure 5 shows the survival curves. The p-value from the log-rank test, adjusted for strata, is 0.039 and the estimated hazard ratio is 0.61 (CI: 0.38-0.98).

Table 17: Duration of Clinical Disease-Free Survival Controlled for FLIPI Risk Group and Number of Chemotherapy Cycles, Untreated Patient-time Excluded (ITT Population, N= 177, Study BV301)

|                                            | Active (N=76)   | Control (N=41)   | P-value   |
|--------------------------------------------|-----------------|------------------|-----------|
| Log-rank test                              |                 |                  | 0.039     |
| Median,months                              | 32.0            | 21.1             |           |
| I0%56                                      | 24.9-52.7       | 17.4-27.6        |           |
| Lengthof follow-up:min-max (median,months) | 4.9-81.8 (53.6) | 4.8-83.2(48.1)   |           |
| Numberofevents                             | 47              | 31               |           |
| Numbercensored                             | 29              | 10               |           |

Active=Dasiprotimut-TBiovest+GM-CSF:Control=KLH-KLH+GM-CSF

Figure 5: Clinical Disease Free Survival from First Vaccination, Controlling for FLIPI Risk Group and Number of Chemotherapy Cycles (ITT Population, N=117, Study BV301)

<!-- image -->

## Summary of main study

The following tables summarise the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Table 18. Summary of Efficacy for trial BV301

| Idiotype (FNHLId1) with Study identifier Design                     | Local GM-CSF in First Complete Remission BV301                                     | Local GM-CSF in First Complete Remission BV301                    | Local GM-CSF in First Complete Remission BV301                                                                                                                                                                                                  | Local GM-CSF in First Complete Remission BV301                                                                                                                                                                                                  | Local GM-CSF in First Complete Remission BV301                                                                                                                                                                                                  | Local GM-CSF in First Complete Remission BV301                                                                                                                                                                                                  |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Idiotype (FNHLId1) with Study identifier Design                     | Randomized, double-blind, controlled, multicenter study                            | Randomized, double-blind, controlled, multicenter study           | Randomized, double-blind, controlled, multicenter study                                                                                                                                                                                         | Randomized, double-blind, controlled, multicenter study                                                                                                                                                                                         | Randomized, double-blind, controlled, multicenter study                                                                                                                                                                                         | Randomized, double-blind, controlled, multicenter study                                                                                                                                                                                         |
| Idiotype (FNHLId1) with Study identifier Design                     | Duration of main phase: Duration of Run-in phase:                                  | Duration of main phase: Duration of Run-in phase:                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |
| Idiotype (FNHLId1) with Study identifier Design                     | Duration of Extension phase:                                                       | Duration of Extension phase:                                      | not applicable Median follow-up: 56.6 months                                                                                                                                                                                                    | not applicable Median follow-up: 56.6 months                                                                                                                                                                                                    | not applicable Median follow-up: 56.6 months                                                                                                                                                                                                    | not applicable Median follow-up: 56.6 months                                                                                                                                                                                                    |
| Hypothesis                                                          | Superiority                                                                        | Superiority                                                       | Superiority                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                     |
| Treatments groups                                                   | Active (Id-KLH + GM-CSF)                                                           | Active (Id-KLH + GM-CSF)                                          | 0.5 mg isotype-matched Id conjugated to 0.5 mg KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months (vaccinations started ≥6 months after completion of induction chemotherapy); 118 patients randomized | 0.5 mg isotype-matched Id conjugated to 0.5 mg KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months (vaccinations started ≥6 months after completion of induction chemotherapy); 118 patients randomized | 0.5 mg isotype-matched Id conjugated to 0.5 mg KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months (vaccinations started ≥6 months after completion of induction chemotherapy); 118 patients randomized | 0.5 mg isotype-matched Id conjugated to 0.5 mg KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months (vaccinations started ≥6 months after completion of induction chemotherapy); 118 patients randomized |
| Treatments groups                                                   | Control (KLH-KLH + GM-CSF)                                                         | Control (KLH-KLH + GM-CSF)                                        | 1 mg KLH-KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months; 59 patients randomized                                                                                                                    | 1 mg KLH-KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months; 59 patients randomized                                                                                                                    | 1 mg KLH-KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months; 59 patients randomized                                                                                                                    | 1 mg KLH-KLH vaccine SC (Day1) + 100 mcg/m 2 /day GM-CSF SC (Days 1 to 4) at 1, 2, 3, 4 and 6 months; 59 patients randomized                                                                                                                    |
| Endpoints and definitions                                           | Primary endpoint Secondary endpoint                                                | Disease Free Survival (DFS)                                       | Duration from randomization to relapse or last follow-up Time from randomization to the date of death                                                                                                                                           | Duration from randomization to relapse or last follow-up Time from randomization to the date of death                                                                                                                                           | Duration from randomization to relapse or last follow-up Time from randomization to the date of death                                                                                                                                           | Duration from randomization to relapse or last follow-up Time from randomization to the date of death                                                                                                                                           |
| Endpoints and definitions                                           |                                                                                    | Overall survival (OS)                                             | due to any reason or last follow-up.                                                                                                                                                                                                            | due to any reason or last follow-up.                                                                                                                                                                                                            | due to any reason or last follow-up.                                                                                                                                                                                                            | due to any reason or last follow-up.                                                                                                                                                                                                            |
| Database lock                                                       | 30-June-2008                                                                       | 30-June-2008                                                      | 30-June-2008                                                                                                                                                                                                                                    | 30-June-2008                                                                                                                                                                                                                                    | 30-June-2008                                                                                                                                                                                                                                    | 30-June-2008                                                                                                                                                                                                                                    |
| Results and Analysis                                                | Primary Analysis                                                                   | Primary Analysis                                                  | Primary Analysis                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                |
| Analysis description Analysis population and time point description |                                                                                    |                                                                   |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                     | Intent to treat (ITT) population. All randomized patients: 177 Treatment Number of | group Active (Id-KLH subject                                      | Intent to treat (ITT) population. All randomized patients: 177 Treatment Number of                                                                                                                                                              | Intent to treat (ITT) population. All randomized patients: 177 Treatment Number of                                                                                                                                                              | Intent to treat (ITT) population. All randomized patients: 177 Treatment Number of                                                                                                                                                              | Intent to treat (ITT) population. All randomized patients: 177 Treatment Number of                                                                                                                                                              |
|                                                                     | (months)                                                                           | (months)                                                          | (months)                                                                                                                                                                                                                                        | (months)                                                                                                                                                                                                                                        | (months)                                                                                                                                                                                                                                        | (months)                                                                                                                                                                                                                                        |
|                                                                     | 95% CI (36.2-63.9) (26.2-39.8)                                                     | 95% CI (36.2-63.9) (26.2-39.8)                                    | 95% CI (36.2-63.9) (26.2-39.8)                                                                                                                                                                                                                  | 95% CI (36.2-63.9) (26.2-39.8)                                                                                                                                                                                                                  | 95% CI (36.2-63.9) (26.2-39.8)                                                                                                                                                                                                                  | 95% CI (36.2-63.9) (26.2-39.8)                                                                                                                                                                                                                  |
|                                                                     | Median OS 90.2 NR                                                                  | Median OS 90.2 NR                                                 | Median OS 90.2 NR                                                                                                                                                                                                                               | Median OS 90.2 NR                                                                                                                                                                                                                               | Median OS 90.2 NR                                                                                                                                                                                                                               | Median OS 90.2 NR                                                                                                                                                                                                                               |
|                                                                     | 95% CI (90.2-NR) (NR-NR)                                                           | 95% CI (90.2-NR) (NR-NR)                                          | 95% CI (90.2-NR) (NR-NR)                                                                                                                                                                                                                        | 95% CI (90.2-NR) (NR-NR)                                                                                                                                                                                                                        | 95% CI (90.2-NR) (NR-NR)                                                                                                                                                                                                                        | 95% CI (90.2-NR) (NR-NR)                                                                                                                                                                                                                        |
| Effect estimate per comparison                                      | Primary endpoint Comparison groups Active vs Control                               | Primary endpoint Comparison groups Active vs Control              | Primary endpoint Comparison groups Active vs Control                                                                                                                                                                                            | Primary endpoint Comparison groups Active vs Control                                                                                                                                                                                            | Primary endpoint Comparison groups Active vs Control                                                                                                                                                                                            | Primary endpoint Comparison groups Active vs Control                                                                                                                                                                                            |
| Effect estimate per comparison                                      | Hazard Ratio 0.58                                                                  | Hazard Ratio 0.58                                                 | Hazard Ratio 0.58                                                                                                                                                                                                                               | Hazard Ratio 0.58                                                                                                                                                                                                                               | Hazard Ratio 0.58                                                                                                                                                                                                                               | Hazard Ratio 0.58                                                                                                                                                                                                                               |
| Effect estimate per comparison                                      | P-value (log-rank) 0.029                                                           | P-value (log-rank) 0.029                                          | P-value (log-rank) 0.029                                                                                                                                                                                                                        | P-value (log-rank) 0.029                                                                                                                                                                                                                        | P-value (log-rank) 0.029                                                                                                                                                                                                                        | P-value (log-rank) 0.029                                                                                                                                                                                                                        |
| Effect estimate per comparison                                      | 95% CI (0.35, 0.95) Secondary Comparison groups Active vs Control                  | 95% CI (0.35, 0.95) Secondary Comparison groups Active vs Control | 95% CI (0.35, 0.95) Secondary Comparison groups Active vs Control                                                                                                                                                                               | 95% CI (0.35, 0.95) Secondary Comparison groups Active vs Control                                                                                                                                                                               | 95% CI (0.35, 0.95) Secondary Comparison groups Active vs Control                                                                                                                                                                               | 95% CI (0.35, 0.95) Secondary Comparison groups Active vs Control                                                                                                                                                                               |
| Effect estimate per comparison                                      | endpoint P-value 0.680                                                             | endpoint P-value 0.680                                            | endpoint P-value 0.680                                                                                                                                                                                                                          | endpoint P-value 0.680                                                                                                                                                                                                                          | endpoint P-value 0.680                                                                                                                                                                                                                          | endpoint P-value 0.680                                                                                                                                                                                                                          |
| Effect estimate per comparison                                      |                                                                                    |                                                                   |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                                      |                                                                                    |                                                                   |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                 |

Analysis performed across trials (pooled analyses and meta-analysis)

N/A

Clinical studies in special populations

N/A

Supportive studies

## Study NCI T93-0164

NCI T93-0164 was a phase 2 randomized (ratio 1:1), parallel-group, open-label study of Id-KLH vaccine administered with 2 different adjuvant doses (100 or 500 µg/m 2  granulocyte-macrophage

<div style=\"page-break-after: always\"></div>

colony-stimulating  factor  [GM-CSF])  as  a  series  of  5  vaccinations  over  6  months  in  follicular lymphoma (FL) patients with complete clinical remission or minimal residual disease status after induction chemotherapy (first patient dose of chemotherapy: 28 October 1993; study termination date: 22 February 2010).

Forty-two adult patients with Stage III or IV lymphoma and no previous treatment for FL (except for treatment  with  radiation  alone  less  than  total  body  irradiation)  were  enrolled.  They  had  tissue diagnosis of follicular small cleaved cell, or follicular mixed lymphoma with surface IgM, IgG, or IgA phenotype with a monoclonal heavy and light chain; a single peripheral lymph node of at least 2 cm size accessible for biopsy/harvest; Karnofsky status ≥ 70% and life expectancy of &gt; 1 year; serum creatinine ≤1.5 mg/dL (unless felt to be secondary to lymphoma), bilirubin≤1.5 mg/dL (unless felt to be secondary to lymphoma or Gilbert's disease), aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT)≤3.5 x upper limit of normal (ULN).

Patients were treated with ProMACE chemotherapy (cyclophosphamide, doxorubicin, etoposide, and prednisone) to best response and were then randomized to 1 of 2 doses of GM-CSF (500 or 100 µg/m 2 /day) to be administered with 0.5 mg of Lympreva (autologous Id-KLH) vaccine.

The primary objectives were to induce cellular and humoral immunity against the unique idiotype (Id) expressed  on  the  surface  of  patients'  B-cell  lymphomas  and  to  determine  the  ability  of  Id immunization  to  eradicate  bcl-2  positive  tumour  cells  from  the  bone  marrow  as  detected  by polymerase chain reaction (PCR). The secondary objectives included the disease free survival (DFS) of patients achieving a complete response (CR) with chemotherapy.

The primary endpoint was molecular complete remission, rate, defined as the percentage of patients who achieved a clinical complete remission to induction therapy but still had cells in their blood from the malignant clone detectable by polymerase chain reaction (PCR) at the end of induction therapy, and who then become PCR negative after the administration of immunotherapy.

Complete molecular remissions were detected in 73% of the evaluable patients, and were maintained for a median of 18+ months after vaccination (range: 8+ to 32+ months). At a median follow-up of 165.7 months (13.82 years), median DFS in the efficacy set was 62.5 months (95% CI 31.3, NR): 84.9 months in patients who received 100 µg/m 2 /day GM-CSF [n=13] vs. 46.8 months in patients who received 500 µg/m 2 /day GM-CSF [n=12] (p=0.411).. Comparisons of complete remission rates and  disease  free  survival  rates  between  the  two  GM-CSF  dose  groups  did  not  reach  statistical significance.

## Study NCI 1033

NCI  1033  was  a  single  centre,  phase  2,  single  arm,  open-label  study  of  Lympreva  vaccine administered with 100 µg/m 2 /day granulocyte-macrophage colony stimulating factor (GM-CSF) as a series of 5 vaccinations over 6 months in untreated Mantle Cell Lymphoma patients who achieved minimal  residual  disease  with  combination  chemotherapy  (etoposide,  doxorubicin,  vincristine, cyclophosphamide, prednisone [EPOCH]) with rituximab (EPOCH-R). First patient dose of EPOCH-R: 23 June 2000; date of last follow-up: 24 August 2011.

Adults patients with tissue diagnosis of mantle cell lymphoma, previously untreated with cytotoxic chemotherapy (local radiation or a short course of steroids for control of symptoms admitted) were enrolled for the study. Patients may have all stages of disease, lymph node of ≥ 2 cm accessible for biopsy/harvest or &gt; 1000/µl of circulating tumour cells in the blood, ECOG performance status ≤ 3, adequate major organ function (serum creatinine 1.5 mg/dl or creatinine clearance &gt; 60 ml/min; bilirubin &lt; 2 mg/dl (total) except &lt; 5 mg/dl in patients with Gilbert's syndrome as defined by &gt; 80% unconjugated; ANC &gt; 1000 and platelets &gt; 100,000) unless impairment due to organ involvement by

<div style=\"page-break-after: always\"></div>

lymphoma. No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year was admitted.

Patients  received  EPOCH-R  (etoposide,  prednisone,  vincristine,  cyclophosphamide,  doxyrubicin, rituximab)  chemotherapy  for  6  cycles,  followed  by  5  vaccinations  with  Dasiprotimut-  T  Biovest. Vaccine treatment was started at least 12 weeks and no more than 12 months after completion of chemotherapy. Each vaccine consisted of Lympreva vaccine administered on Day 0. The vaccine was administered together with 100 µg/m 2 /day GM-CSF on Days 0-3 as an immunological adjuvant.

Primary objectives were to assess progression free survival (primary endpoint: PFS for at least 4 weeks after EPOCH-R completion, with 36 months) and the tumour specific T-cell response.

Median PFS was 24.1 months (95% CI: 21.12 - 31.05). The results of the clinical response analysis results are reported in Table 19.

Table 19:  EPOCH-R Clinical Response (Study NCI 1033)

|                             | (N=26)   | Total(All Patients)95%6 Confidence Interval   |
|-----------------------------|----------|-----------------------------------------------|
| Response to EPOCH-R Therapy |          |                                               |
| CR                          | 24 (92%) | 76% - 98%                                     |
| CRu                         | 0 (0%)   | 0% - 13%                                      |
| PR                          | 2 (8%)   | 2%6 - 24%                                     |
| SD*                         | 0 (0%)   | 0% - 13%                                      |
| PD                          | 0 (0%)   | 0% - 13%                                      |

Abbreviations: CR = complete response; CRu = complete response mconfimed; EPOCH-R = etoposide, prednisone,vincristine,cyclophosphamide,doxorubicin,rihximab; PD = progressive disease;PR=partial response; SD = stable disease Note: Percentages are calculated based on the number of patients who had at least one valid assessment.The 95% CI was caleulated using a binomial dishibution.

<div style=\"page-break-after: always\"></div>

## 2.6.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The Applicant submitted one pivotal phase III study (BV301), one supportive phase II study (NCI T93-0164) and one bridging phase II study (NCI 1033) in mantle cell lymphoma.

The  pivotal  study  was  a  double-blinded,  randomised,  two-arm,  multicenter  and  place-controlled phase III study. However, due to the introduction of rituximab and other changes, accrual rates were low  and  the  study  was  terminated  prematurely.  Consequently,  the  planned  sample  size  of  540 patients could not be reached.

In  Study  BV301, of the 234 patients with previously untreated follicular lymphoma enrolled 177 (75.6%)  who  achieved  CR/CRu  after  PACE  chemotherapy  were  randomized  to  blinded  vaccine therapy (Lympreva+GM-CSF or KLH-KLH+GM-CSF). A majority of patients who were not randomized were withdrawn due to failure to achieve CR. The study population had a mean and median age significantly younger (by approximately 10 years) than population based reports on FL. A total of 118 patients  were  randomized  to  Lympreva+GMCSF,  of  whom  72  patients  completed  treatment  per protocol. Fifty-nine patients were randomized to KLHKLH+ GM-CSF, of whom 39 patients completed treatment per protocol. The arms were well balanced considering age, lymphoma stage and IPI risk group (FLIPI risk groups were introduced post-hoc and were also reasonably well balanced between the two arms).

The intensive induction regimen (PACE) needed to induce CR from FL before vaccination has not been compared with standard of care treatments at time of study initiation especially with regard to the use of anti CD20 antibodies, the mainstay of current clinical practice. Therefore, 'bridging' of clinical efficacy of Dasiprotimut-T to regimens other than that used in the BV 301 study is not possible.

## Efficacy data and additional analyses

In the pivotal study BV301, median DFS was 46.0 months for patients in the active treatment group versus 30.6 months for patients in the control treatment group (HR=0.029, 95% CI [0.35, 0.95], (log-rank p value=0.029). However, this difference in DFS between the two arms is limited to the subpopulation  that  underwent  vaccination  and  it    was  calculated  by  including  only  patients  who achieved CR/CRu after induction with PACE (ie, study treatment 1) and underwent randomisation (2:1) between active and control vaccination (ie, study treatment 2). Disease relapse prior to vaccine was the primary reason for patients being censored in either active or treatment arm (83.3% and 88.9%, respectively). The CHMP raised a major objection about this analysis considering questionable the  DFS  benefit  from  a  methodological  and  clinical  perspective.  Based  on  this,  a  new  analysis representing all events recorded in the ITT population has been submitted by the applicant. In the new DFS analysis the benefits seen for the patients in the active vaccination arm were considerably diminished. The Kaplan-Meier estimated median duration of DFS was 20.1 months vs. 20.6 months in the active arm and control arm, respectively (adjusted log-rank p 0.295).

More than 50% of the patients had FLIPI score of 0-1 and only 12% had FLIPI score 3-5. From a conventional perspective, the need for therapy may thus be questioned in a non-trivial proportion of the population and the induction regimen (PACE) must be regarded as experimental and of high intensity with unproven positive B/R, especially in these patients.

The small supportive study NCI T93-1064 reports biologically active immune responses demonstrated in larger and smaller subgroups of the enrolled patients, but the influence on clinical parameters such as DFS and OS remain elusive. Furthermore, the results clearly imply that an immune response to tumour Id, whether humoral or cellular, does not entail long term survival or cure.

<div style=\"page-break-after: always\"></div>

Finally,  the  study  NCI  1033  in  MCL  showed  that  both  cellular  and,  to  a  limited  extent,  humoral immune responses could be elicited in the MCL patients after achieving CR on chemoimmune therapy. However, there was a lack of standardization of definitions used for meaningful immune responses in this study compared to the earlier study NCI T90-1064. This study provides no strong supportive evidence for the FL indication.

## 2.6.4. Conclusions on the clinical efficacy

No  significant  difference  in  DFS  was  shown  between  subjects  randomised  to  active  vs.  control vaccination  (log-rank  p-value  0.295),  and  the  same  was  observed  for  all  subgroups  analysed. Therefore, efficacy for Dasiprotimut-T has not been demonstrated in the pivotal study.

In addition, notwithstanding the fact that efficacy has not been established, the intensive induction regimen (PACE) used to induce CR from FL before vaccination is not standard of care. There are no data  to  show  clinical  efficacy  of  Dasiprotimut-T  with  induction  regimens  used  in  current  clinical practice.  In view of the important differences between the PACE regimen and the current regimens that include CD20 antibodies, it is not possible to generalise the effect observed between regimens.

## 2.7. Clinical safety

The safety analysis of of Lympreva was based on the pooled population (Summary Safety Population, N=179) of the following 3 different groups, from the studies BV301 (safety population: 71 subjects with active vaccination and 46 controls, with FL), NCI T93-0164 (safety population: 37 subjects with FL treated with active vaccination) and NCI 1033 (safety population: 26 subjects with MCL treated with active vaccination):

- Lympreva with 100 mcg/m 2  GM-CSF group, including all patients who received blinded or unblinded vaccinations in this formulation from the BV301, NCI T93-0164 and NCI 1033 studies (N=115);
- Lympreva with 500 mcg/m 2  GM-CSF group, including all patients from Study NCI T93-0164 who received vaccinations in this formulation (unblinded) (N=18);
- The KLH-KLH control with 100 mcg/m 2  GM-CSF group, including all patients from Study BV301 who received this vaccination formulation (blinded) (N= 46).

Adverse events (AEs)  were collected during vaccine administration and up to 30 days after last vaccine dose.

## Patient exposure

In the BV301 study, median duration of vaccine therapy was 4.7 months and ≥94% subjects received the complete 5 course planned vaccination in both arms. In the NCI 1033 study median duration of vaccine therapy was 4.7 months (92% of patients received 5 vaccinations) and in the NCI T93-0164 study therapy was administered for a mean 4.6 months (92% of subjects received 5 vaccinations).

Overall, mean duration of vaccine exposure was 4.7 months across all studies.

## Adverse events

The most common TEAE in the Summary Safety Population was injection site reaction, which was reported for 129 patients (72.1%): 78 (67.8%) patients in the Lympreva with GM-CSF 100 µg/m 2 treatment group, 11 patients (62.2%) in the Lympreva with GM-CSF 500 µg/m 2  treatment group, and 40  patients  (87.0%)  in the  KLH-KLH  with  GM-CSF  100  µg/m 2   control  group.  Of  the  351

<div style=\"page-break-after: always\"></div>

vaccinations administered,  286  (81.5%)  vaccinations  demonstrated  erythema,  210  (59.8%) vaccinations demonstrated induration and 5 (1.5%) demonstrated ulceration.

Following injection site reactions, the next most common TEAEs were fatigue (85 patients, 47.5%), myalgia (74 patients, 41.3%), and arthralgia (64 patients, 35.8%). The additional following TEAEs had an incidence of &gt;20% for the overall Summary Safety Population: headache, pruritus, erythema, and nausea.

In the Lympreva with GM-CSF 100 µg/m 2  treatment group, 26.9% of patients experienced TEAEs of severity ≥Grade 3. TEAEs with a severity ≥Grade 3  experienced by &gt;1% of the patients from the overall  safety  population  were:  Neutrophil  count  decreased,  White  blood  cell  count,  Lymphocyte count  decreased,  Anaphylactic  reaction,  Arthralgia,  Diarrhoea,  Dyspnoea,  Headache,  Induration, Injection site reaction, Pain, Sinusitis, Urticaria, and Vomiting.

## · Study BV301 (FL)

An overview of Treatment Emergent Adverse Events is presented in Table 20.

## Table 20: Overview of Treatment-Emergent Adverse Events from Newer CRF (Safety Population, N=117 - Study BV301)

<div style=\"page-break-after: always\"></div>

| Subjects, n (%)                                                                       | Actlve (N=71)   | Control (N=46)   | Overall (N=117)   |
|---------------------------------------------------------------------------------------|-----------------|------------------|-------------------|
| With at least 1 TEAE                                                                  | 51 (71.8)       | 35 (76.1)        | 86 (73.5)         |
| With at least l serious TEAE                                                          | 6 (8.5)         | 6 (13.0)         | 12 (10.3)         |
| With at least 1 TEAE related to Vaccine                                               | 33 (46.5)       | 24 (52.2)        | 57 (48.7)         |
| With at least 1 TEAE related to GM-CSF                                                | 37 (52.1)       | 25 (54.3)        | 62 (53.0)         |
| With at least 1 NCI CTCAE Grade 3/4 TEAE related to Vaccine                           | 5 (7.0)         | 1 (2.2)          | 6 (5.1)           |
| With at least 1 NCI CTCAE Grade 3/4 TEAE related to GM-CSF                            | 5 (7.0)         | 1 (2.2)          | 6 (5.1)           |
| With at least 1 serious TEAE related to Vaccine                                       | 3 (4.2)         | 2 (4.3)          | 5 (4.3)           |
| With at least 1 serious TEAE related to GM-CSF                                        | 3 (4.2)         | 2 (4.3)          | 5 (4.3)           |
| With at least 1 NCI CTCAE Grade 5 TEAE related to study drug'                         | 0 (0.0)         | 0 (0.0)          | 0 (0.0)           |
| With at least 1 TEAE related to study drug* leading to dose reduction                 | 0 (0.0)         | 0 (0.0)          | 0 (0.0)           |
| With at least 1 TEAE related to study drug* leading to temporary regimen interruption | 1 (1.4)         | 1 (2.2)          | 2 (1.7)           |
| With at least 1 TEAE related to Vaccine leading to temporary regimen interruption     | 0 (0.0)         | 1 (2.2)          | 1 (0.9)           |
| With at least 1 TEAE related to GM-CSF leading to temporary regimen interruption      | 1 (1.4)         | 1 (2.2)          | 2 (1.7)           |
| With at least 1 TEAE related to Vaccine leading to permanent regimen interruption     | 1 (1.4)         | 0 (0.0)          | 1 (0.9)           |
| With at least 1 TEAE related to GM-CSF leading to permanent regimen interruption      | 1 (1.4)         | 0 (0.0)          | 1 (0.9)           |
| Deaths on Study&                                                                      | 0 (0.0)         | 0 (0.0)          | 0 (0.0)           |

* Study drug here relates to either dasiprotimut-T Biovest + GM-CSF or KLH + GM-CSE.

Death on study defined here are deaths occurring during vaccine administration or within 30 days from last vaccine administration.

Active = dasiprotimut-T Biovest + GM-CSF; Control = KLH-KLH + GM-CSF

GM-CSF = granulocyte macrophage colony-stimulating factor, KLH = keyhole limpet hemocyanin, TEAE = Treatment-emergent adverse event, NCI CTC = National Cancer Institute Common Terminology Criteria

Safety Population includes all randomized subjects who received at least one dose of active or control vaccine as treated.

Treatment Emergent Adverse Events by Body System and Preferred Term are reported in Table 21.

<div style=\"page-break-after: always\"></div>

Table 21: Overall Treatment Emergent Adverse Events Reported by ≥ 5% of Patients in Either Treatment Group, by Body System and Preferred Term (Safety Population, N= 117 Study BV301)

|                                                 | Actlve (N=71)                                   | Actlve (N=71)   | Control (N=46)   | Control (N=46)   | AII Patlents (N=117)   | AII Patlents (N=117)   |       |
|-------------------------------------------------|-------------------------------------------------|-----------------|------------------|------------------|------------------------|------------------------|-------|
| SO C/Preferred Term                             | n                                               | %               | n                | %                | n                      | %                      | pt    |
| Vascular disorders                              |                                                 |                 |                  |                  |                        |                        |       |
| Flushing                                        | 8                                               | 11.3            | 2                | 4.3              | 10                     | 8.5                    | 0.312 |
| Hot flush                                       | 5                                               | 7.0             | 2                | 4.3              | 7                      | 6.0                    | 0.703 |
| Hypertension                                    | 4                                               | 5.6             | 1                | 2.2              | 5                      | 4.3                    | 0.647 |
| Hypotension                                     | 4                                               | 5.6             |                  | 2.2              | 5                      | 4.3                    | 0.647 |
| Surglcal and medical procedures                 |                                                 |                 |                  |                  |                        |                        |       |
| Skin and subcutaneous tissue disorders          |                                                 |                 |                  |                  |                        |                        |       |
| Pruritus                                        | 15                                              | 21.1            | 11               | 23.9             | 26                     | 22.2                   | 0.821 |
| Hyperhidrosis                                   | 11                                              | 15.5            | 3                | 6.5              | 14                     | 12.0                   | 0.243 |
| Rash maculo-papular                             | 6                                               | 8.5             | 4                | 8.7              | 10                     | 8.5                    | 1.000 |
| Urticaria                                       | 6                                               | 8.5             | 2                | 4.3              | 8                      | 6.8                    | 0.478 |
| Palmar-plantar erythrodysaesthesia syndrome     | 2                                               | 2.8             | 3                | 6.5              | 5                      | 4.3                    | 0.380 |
| Resplratory, thoraclc and mediastinal disorders | Resplratory, thoraclc and mediastinal disorders |                 |                  |                  |                        |                        |       |
| Cough                                           | 11                                              | 15.5            | 4                | 8.7              | 15                     | 12.8                   | 0.398 |
| Dyspnoea                                        | 5                                               | 7.0             | 4                | 8.7              | 9                      | 7.7                    | 0.737 |
| Rhinitis allergic                               | 2                                               | 2.8             | 5                | 10.9             | 7                      | 6.0                    | 0.110 |
| Reproductive system and breast disorders        |                                                 |                 |                  |                  |                        |                        |       |
| Renal and urlnary disorders                     |                                                 |                 |                  |                  |                        |                        |       |
| Pollakiuria                                     | 5                                               | 7.0             | 0                | 0.0              | 5                      | 4.3                    | 0.155 |
| Psychiatrlc disorders                           |                                                 |                 |                  |                  |                        |                        |       |
| Depression                                      | 4                                               | 5.6             | 1                | 2.2              | 5                      | 4.3                    | 0.647 |
| Hallucination                                   | 3                                               | 4.2             | 3                | 6.5              | 6                      | 5.1                    | 0.678 |

<div style=\"page-break-after: always\"></div>

## Nervous system disorders

| Headache                                                            | 28                                                                  | 39.4                                                                | 15                                                                  | 32.6                                                                | 43                                                                  | 36.8                                                                | 0.557                                                               |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Depressed level of consciousness                                    | 6                                                                   | 8.5                                                                 | 2                                                                   | 4.3                                                                 | 8                                                                   | 6.8                                                                 | 0.478                                                               |
| Peripheral sensory neuropathy                                       | 2                                                                   | 2.8                                                                 | 3                                                                   | 6.5                                                                 | 5                                                                   | 4.3                                                                 | 0.380                                                               |
| Dizziness                                                           | 1                                                                   | 1.4                                                                 | 4                                                                   | 8.7                                                                 | 5                                                                   | 4.3                                                                 | 0.077                                                               |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     | Musculoskeletal and connectlve tissue disorders                     |
| Myalgia                                                             | 29                                                                  | 40.8                                                                | 17                                                                  | 37.0                                                                | 46                                                                  | 39.3                                                                | 0.703                                                               |
| Arthralgia                                                          | 25                                                                  | 35.2                                                                | 17                                                                  | 37.0                                                                | 42                                                                  | 35.9                                                                | 0.847                                                               |
| Bone pain                                                           | 15                                                                  | 21.1                                                                | 10                                                                  | 21.7                                                                | 25                                                                  | 21.4                                                                | 1.000                                                               |
| Back pain                                                           | 8                                                                   | 11.3                                                                | 2                                                                   | 4.3                                                                 | 10                                                                  | 8.5                                                                 | 0.312                                                               |
| Muscular weakness                                                   | 3                                                                   | 4.2                                                                 | 3                                                                   | 6.5                                                                 | 6                                                                   | 5.1                                                                 | 0.678                                                               |
| Musculoskeletal pain                                                | 0                                                                   | 0.0                                                                 | 3                                                                   | 6.5                                                                 | 3                                                                   | 2.6                                                                 | 0.058                                                               |
| Metabolism andnutrltion disorders                                   |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Hyperglycaemia                                                      | 10                                                                  | 14.1                                                                | 1                                                                   | 2.2                                                                 | 11                                                                  | 9.4                                                                 | 0.048                                                               |
| Decreased appetite                                                  | 5                                                                   | 7.0                                                                 | 2                                                                   | 4.3                                                                 | 7                                                                   | 6.0                                                                 | 0.703                                                               |
| Investigatlons                                                      |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| White blood cell count decreased                                    | 5                                                                   | 7.0                                                                 | 1                                                                   | 2.2                                                                 | 6                                                                   | 5.1                                                                 | 0.401                                                               |
| Injury, polsoning and procedural complicatlons                      |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Contusion                                                           | 2                                                                   | 2.8                                                                 | 3                                                                   | 6.5                                                                 | 5                                                                   | 4.3                                                                 | 0.380                                                               |
| Infectionsand infestations                                          |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Infection                                                           | 7                                                                   | 9.9                                                                 | 2                                                                   | 4.3                                                                 | 9                                                                   | 7.7                                                                 | 0.480                                                               |
| Sinusitis                                                           | 0                                                                   | 0.0                                                                 | 3                                                                   | 6.5                                                                 | 3                                                                   | 2.6                                                                 | 0.058                                                               |
| Immunesystemdisorders                                               |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Hypersensitivity                                                    | 3                                                                   | 4.2                                                                 | 4                                                                   | 8.7                                                                 | 7                                                                   | 6.0                                                                 | 0.431                                                               |
| General disordersandadministrationsiteconditlons                    |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Injection site reaction                                             | 68                                                                  | 95.8                                                                | 40                                                                  | 87.0                                                                | 108                                                                 | 92.3                                                                | 0.152                                                               |
| Fatigue                                                             | 40                                                                  | 56.3                                                                | 24                                                                  | 52.2                                                                | 64                                                                  | 54.7                                                                | 0.706                                                               |
| Pyrexia                                                             | 16                                                                  | 22.5                                                                | 10                                                                  | 21.7                                                                | 26                                                                  | 22.2                                                                | 1.000                                                               |
| Non-cardiac chest pain                                              | I1                                                                  | 15.5                                                                | 5                                                                   | 10.9                                                                | 16                                                                  | 13.7                                                                | 0.587                                                               |
| Pain                                                                | 9                                                                   | 12.7                                                                | 5                                                                   | 10.9                                                                | 14                                                                  | 12.0                                                                | 1.000                                                               |
| Chills                                                              | 6                                                                   | 8.5                                                                 | 10                                                                  | 21.7                                                                | 16                                                                  | 13.7                                                                | 0.054                                                               |
| Influenza like illness                                              | 6                                                                   | 8.5                                                                 | 2                                                                   | 4.3                                                                 | 8                                                                   | 6.8                                                                 | 0.478                                                               |
| Chest pain                                                          | 5                                                                   | 7.0                                                                 | 3                                                                   | 6.5                                                                 | 8                                                                   | 6.8                                                                 | 1.000                                                               |
| Oedema                                                              | 4                                                                   | 5.6                                                                 | 0                                                                   | 0.0                                                                 | 4                                                                   | 3.4                                                                 | 0.153                                                               |
| Unevaluable event                                                   | 3                                                                   | 4.2                                                                 | 3                                                                   | 6.5                                                                 | 6                                                                   | 5.1                                                                 | 0.678                                                               |
| Injection site pain                                                 | 0                                                                   | 0.0                                                                 | 3                                                                   | 6.5                                                                 | 3                                                                   | 2.6                                                                 | 0.058                                                               |
| Gastrointestinal disorders                                          |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Nausea                                                              | 16                                                                  | 22.5                                                                | 11                                                                  | 23.9                                                                | 27                                                                  | 23.1                                                                | 1.000                                                               |
| Diarrhoea                                                           | 12                                                                  | 16.9                                                                | 4                                                                   | 8.7                                                                 | 16                                                                  | 13.7                                                                | 0.275                                                               |
| Dyspepsia                                                           | 12                                                                  | 16.9                                                                | 4                                                                   | 8.7                                                                 | 16                                                                  | 13.7                                                                | 0.275                                                               |
| Abdominal pain                                                      | 11                                                                  | 15.5                                                                | 4                                                                   | 8.7                                                                 | 15                                                                  | 12.8                                                                | 0.398                                                               |
| Vomiting                                                            | 8                                                                   | 11.3                                                                | 3                                                                   | 6.5                                                                 | 11                                                                  | 9.4                                                                 | 0.524                                                               |
| Constipation                                                        | 6                                                                   | 8.5                                                                 | 0                                                                   | 0.0                                                                 | 6                                                                   | 5.1                                                                 | 0.080                                                               |
| Stomatitis                                                          | 4                                                                   | 5.6                                                                 | 0                                                                   | 0.0                                                                 | 4                                                                   | 3.4                                                                 | 0.153                                                               |
| Eye disorders                                                       |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Ear and labyrlnth disorders                                         |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Cardiac disorders                                                   |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Blood and Iymphatlc system disorders                                |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |

Fisher's exact test was used for group comparisons.

MedDRA v. 16.0 was used to code adverse events.

Aclive = dasiprotimut-T Biovest + GM-CSF; Control = KLH-KLH + GM-CSF

Treatment Emergent Adverse Events by Severity are shown in Table 22:

<div style=\"page-break-after: always\"></div>

Table 22: Summary of Treatment-emergent Adverse Events Reported by ≥ 10% of Patients in Either Treatment Group by Severity (Safety Population - Study BV301)

|                                                     | Mild                                                | Mild                                                | Moerale       | Moerale        | Severe        | Severe         |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|---------------|----------------|---------------|----------------|
| Body System/ Adverse Event, n (95)                  | Active (N=71)                                       | Control (N=46)                                      | Active (N=71) | Control (N=46) | Aetive (N=71) | Control (N=46) |
| Vaseular Disorders                                  |                                                     |                                                     |               |                |               |                |
| Flushing                                            | 8 (11.3)                                            | 2 (4.3)                                             | 0             | 0              | 0             | 0              |
| Skin and Subeutaneous Tissue Disorders              | Skin and Subeutaneous Tissue Disorders              |                                                     |               |                |               |                |
| Pruritus                                            | 15 (21.1)                                           | 10 (21.7)                                           | 1 (1.4)       | 2 (4.3)        | 0             | 0              |
| Hyperhidrosis                                       | 11 (15.5)                                           | 2 (4.3)                                             | 1 (1.4)       | 1 (2.2)        | 0             | 0              |
| Respiratory, Thoracic and Mediastinal Disorders     | Respiratory, Thoracic and Mediastinal Disorders     |                                                     |               |                |               |                |
| Cough                                               | 10 (14.1)                                           | 2 (4.3)                                             | 1(1.4)        | 2 (4.3)        | 0             | 0              |
| Nervous System Disorders                            |                                                     |                                                     |               |                |               |                |
| Headache                                            | 26 (36.6)                                           | 14 (30.4)                                           | 7 (9.9)       | 5 (10.9)       | 1(1.4)        | 1(2.2)         |
| Musculoskeletal and Connective Tissue Disorders     | Musculoskeletal and Connective Tissue Disorders     |                                                     |               |                |               |                |
| Myalgia                                             | 28 (39.4)                                           | 15 (32.6)                                           | 5 (7.0)       | 4 (8.7)        | 0             | 0              |
| Arthralgia                                          | 24 (33.8)                                           | 13 (28.3)                                           | 5 (7.0)       | 7 (15.2)       | 1 (1.4)       | 1 (2.2)        |
| Bone pain                                           | 12 (16.9)                                           | 4 (8.7)                                             | 3(4.2)        | 7 (15.2)t      | 0             | 0              |
| Metabolism and Nutrition Disorders                  | Metabolism and Nutrition Disorders                  |                                                     |               |                |               |                |
| Hyperglycaemia                                      | 9 (12.7)                                            | 0                                                   | 1(1.4)        | 1 (2.2)        | 0             | 0              |
| General Disorders and AdministrationSite Conditions | General Disorders and AdministrationSite Conditions | General Disorders and AdministrationSite Conditions |               |                |               |                |
| Injection site reaction                             | 61 (85.9)                                           | 37 (80.4)                                           | 21 (29.6)     | 17 (37.0)      | 1(1.4)        | 0              |
| Fatigue                                             | 37 (52.1)                                           | 24 (52.2)                                           | 10(14.1)      | 2 (4.3)        | 1 (1.4)       | 0              |
| Pyrexia                                             | 15 (21.1)                                           | 10 (21.7)                                           | 3 (4.2)       | 0              | 0             | 0              |
| Pain                                                | 9 (12.7)                                            | 5 (10.9)                                            | 1 (1.4)       | 0              | 0             | 1 (2.2)        |
| Non-cardiac chest pain                              | 8 (11.3)                                            | 3 (6.5)                                             | 5 (7.0)       | 3 (6.5)        | 0             | 0              |
| Chills                                              | 6(8.5)                                              | 10 (21.7)                                           | 1 (1.4)       | 0              | 0             | 0              |
| Gastrointestinal Disorders                          | Gastrointestinal Disorders                          |                                                     |               |                |               |                |
| Nausea                                              | 14 (19.7)                                           | 11 (23.9)                                           | 3(4.2)        | 3 (6.5)        | 0             | 0              |
| : Diarrhoea                                         | 11 (15.5)                                           | 4 (8.7)                                             | 1(1.4)        | 1 (2.2)        | 1 (1.4)       | 0              |
| Dyspepsia                                           | 11 (15.5)                                           | 2 (4.3)                                             | 1 (1.4)       | 2 (4.3)        | 1 (1.4)       | 0              |
| Abdominal pain                                      | 9 (12.7)                                            | 3 (6.5)                                             | 3(4.2)        | 1 (2.2)        | 1 (1.4)       | 0              |

Aclive = Dasiprotimut-T Biovest+GM-CSF; Control = KLH-KLH+GM-CSF

GM-CSF = granulocyte macrophage colony-stimulating factor; KLH = keyhole limpet hemocyanin

tP = 0.048; Fisher's exact test was used for group comparison.

## Adverse Events of special interest

## Injection site reactions

All patients who received Lympreva with GM-CSF reported injection site reactions during the course of the therapy. In 81.7% of patients, injection site reactions were mild or moderate. The most common reactions were erythema (72.2%), induration (66.1%), pruritus (43.5%), and pain (20%).

In the control trial, erythema reactions between 1 and 10 cm were reported in 62% of patients during the duration of the treatment. The incidence of erythema reactions increased progressively during the first four immunizations (48.8% at the first vaccine, 80% at the second vaccine, 87.5% at the third and fourth vaccine, and 84.7% at the fifth vaccine). Induration reactions between 1 and 10 cm were reported in 49.5% of patients. The incidence of induration reactions increased progressively during the first four immunizations (23.7% at the first vaccine, 64.5% at the second vaccine, 67.1% at the third vaccine, 78.4% at the fourth vaccine, and 62.5% at the fifth vaccine). Ulceration reactions were reported in 8.4% of patients. Size of ulceration reactions were reported as follows: 1.4% measured &gt;10 cm, 2.8% measured 1-10 cm, and 4.2% measured &lt;1 cm.

In the controlled trial, severe (grade 3) induration was reported each in 1.4% of patients.

<div style=\"page-break-after: always\"></div>

Such  injection  site  reactions  are  known  to  be  associated  distinctly  with  GM-CSF  and  the  KLH component of  Lympreva.  In  patients  who  experience  a  reaction  suggestive  of  sensitization,  the Dasiprotimut- T and GM-CSF must be administered in separate syringes and at distant injection sites.

## Hyperglycaemia

In  the  study  BV301,  10  patients in  the  active  treatment  group  versus  1  patient  in  the  control treatment group reported at least 1 TEAE hyperglycaemia. Two of them (1 each in the active and control treatment groups) had an ongoing history of diabetes.

None of the patients with treatment-emergent hyperglycaemia had dosing changes, interruptions or discontinuations due to the events.

## Secondary malignancies

Eight  of  the  10  patients  reporting  secondary  malignancies  in  the  study  BV301  were  on  active treatment  (11.3%,  control  arm  4.3%);  in  2  of  these,  two  different  malignancies  were  reported (adenocarcinoma of the liver + squamous cell carcinoma; melanoma + B cell leukemic malignancy). One case of AML occurred in the active treatment arm and one case of MDS/AML occurred in the control arm. No pattern in terms of histology or temporal trend was noted.

## · Study NCI 1033 (MCL)

An overview of Treatment Emergent Adverse Events in Study NCI 1033 is presented in Table 23.

Table 23: Overall Summary of Treatment-Emergent Adverse Events (Safety Set, - Study NCI 1033)

| Variable                                                                               | During EPOCH-R Therapy   | During Vaccination Therapy   |
|----------------------------------------------------------------------------------------|--------------------------|------------------------------|
| Number of Subjects                                                                     | 26                       | 25                           |
| Nuumber of subjects with one or more TEAE, n (%)                                       | 26 ( 100 %)              | 22 ( 88 %)                   |
| Number of TEAEs                                                                        | 1420                     | 134                          |
| Number of subjeets with one or more serious TEAE, n (%)                                | 2 ( 7.69 %)              | 1 (4%)                       |
| Nuumber of serious TEAEs                                                               | 2                        |                              |
| Number of subjects with one or more related TEAE, n (%)                                | 26 ( 100 %)              | 18 ( 72 %)                   |
| Number of related TEAEs                                                                | 1387                     | 71                           |
| Number of subjeets with one or more serious and related * TEAE, n (%)                  | 2 ( 7.69 %)              | 1(4%)                        |
| Number of serious and related TEAEs                                                    | 2                        | 3                            |
| Number of TEAEs leading to study drug discontinuation                                  | 12                       | 0                            |
| Nuumber of subjects with one or more TEAE leading to study drug discontinuation, n (%) | 2 ( 7.69 %)              | 0 (0%)                       |

During vaccine therapy the following Treatment Emergent Events by Preferred Term were reported in ≥8% of subjects (= in ≥2 patients): neutrophil count decreased (36%), platelet count decreased (8%),  WBC  decreased  (32%),  lymphocyte  count  decreased  (36%),  ALP  increased  (8%),  AST increased (8%), diarrhoea (12%), arthralgia (8%), fatigue (8%), anaemia (12%), hyperglycaemia (24%), and hypomagnesaemia (12%).

Treatment Emergent Adverse Events by Severity are shown in Table 24.

<div style=\"page-break-after: always\"></div>

Table 24: Treatment Emergent Adverse Events During Vaccine Therapy by Severity (Safety Set - Study NCI 1033)

| $OC.PT.n()                                                                | Vaccine Gnde 1 (N=25)   | Vhccine Gnde 2 (N=25)   | Vaccine Grade 3 (N= 25)   | Vaecine Grade 4 (N = 25)   |
|---------------------------------------------------------------------------|-------------------------|-------------------------|---------------------------|----------------------------|
| Overall                                                                   |                         |                         |                           |                            |
| Subjects with any events                                                  | 18 (7296)               | 12 (48%)                | 11 (4496)                 | 6 (2496)                   |
| Investigations                                                            |                         |                         |                           |                            |
| bnvestigahons,n                                                           | 9 (36%6)                | 10 (40%)                | 7(28%)                    | 5 (2096)                   |
| Aspartate aminotransferase incrcased                                      | 2 (8%6)                 | 0 (0%)                  | 0 (0%)                    | 0 (096)                    |
| Blood allaline phosphatase increased                                      | 2 (86)                  | 0 (096)                 | 0 (0%)                    | (960)0                     |
| Platelet count decreased                                                  | 2 ($.6)                 | 0 (096)                 | 0 (0%)                    | 0 (0%5)                    |
| White blood cell count decreased                                          | 2 (86)                  | 4 (16%)                 | 2(8%)                     | 4 (16%5)                   |
| Alnine aminotnusferase increased                                          | 1 (4%6)                 | 0 (0%)                  | 0 (0%)                    | (%0)0                      |
| Blood bilinubin inereased                                                 | 1 (4%6)                 | 0 (0%%)                 | 0 (0%)                    | 0 (0%)                     |
| Blood creatine phosphokinase increased                                    | 1 (4%6)                 | 0 (0%)                  | 0 (0%)                    | 0 (0%)                     |
| Intemational nomalised ratioincreased                                     | 1 (496)                 | 0 (0%6)                 | (%60)0                    | 0 (0%6)                    |
| Neutrophil count decreased                                                | 1 (4%6)                 | 1 (496)                 | 4(16%)                    | 5 (20%)                    |
| Lymphocyte count decreased                                                | 0 (06)                  | 7 (289%)                | 4(16)                     | (%0)0                      |
| Metabolism and nutridon disorders                                         |                         |                         |                           |                            |
| Metabolism and mubition disordersAy                                       | 10 (40%6)               | 1 (4%)                  | 1 (4%)                    | (%0)0                      |
| Hyperglycaemia                                                            | 5 (206)                 | 1 (49%)                 | 0 (0%)                    | 0 (0%6)                    |
| Hypomagmesnemia                                                           | 2 (8%6)                 | 0 (0%6)                 | 1 (4%)                    | 0 (086)                    |
| Decreased appetite                                                        | 1 (4)                   | 0 (0%6)                 | (%60) 0                   | 0 (0%)                     |
| Hyperealeaemtia                                                           | 1 (4%)                  | 0 (0%)                  | 0 (0%)                    | (%0）0                      |
| Hypemmsgnesaemia                                                          | 1(4)                    | 0 (0%%)                 | 0 (0%)                    | (%0)0                      |
| Hypoalbuminaenua                                                          | 1 (4)                   | 0 (0%%)                 | 0 (0%)                    | (%0)0                      |
| General disorders and ndininistration site condidions                     |                         |                         |                           |                            |
| General disordersandadmnisnanionsire                                      | 5 (20%6)                | 1 (4%)                  | (%0)0                     | (%60)0                     |
| condinons, dny                                                            |                         |                         |                           |                            |
| Faligue                                                                   | 2 ($%6)                 | 0 (0%%)                 | 0 (0%)                    | 0 (0%)                     |
| Non-eardiae chest pain                                                    | 1 (4%6)                 | 0 (0%)                  | 0(0%)                     | (%0)0                      |
| Oedema                                                                    | 1 (496)                 | 0 (0%%)                 | 0 (0%)                    | 0 (0%)                     |
| Pain                                                                      | 1 (4%6)                 | 0 (0%)                  | 0 (0%)                    | (9%0)0                     |
| Unevaluable event                                                         | (980)0                  | 1 (4%)                  | (%%0)0                    | 0 (06)                     |
| Mfuseuloskeletaland connecdive tissue dis-                                |                         |                         |                           |                            |
| orders Mhsculoskeletalandconneclhvefissue                                 | 3 (1246)                | 0 (0%)                  | 0 (0%%)                   | 0 (0%6)                    |
| disorders,dy Arthralgia                                                   | 2 ($96)                 | 0 (0%)                  | 0 (0%6)                   | 0 (0%%)                    |
| Bone pain                                                                 | 1 (496)                 | (%%0)0                  | 0 (0%6)                   | (960)0                     |
| Blood and lywphatie system disorders Blood and bmphatfe system disorders, | 3 (1246)                | 0 (0%)                  | 0 (0%6)                   | 0 (0%6)                    |
| Annemia                                                                   | 3 (12%6)                | (%%0)0                  | (9%0) 0                   | 0 (086)                    |
| Gastrointestinal disorders                                                |                         |                         |                           |                            |
| Gashontutinal disordes,dy                                                 | 4 (16%)                 | 0 (0%)                  | 0 (0%%)                   | 0 (0%6)                    |
| Dianhoea                                                                  | 3 (12%6)                | 0 (0%)                  | 0 (0%)                    | 0 (0%%)                    |
| Abdominal pain                                                            | 1 (49)                  | (%0)0                   | 0 (0%6)                   | (960)0                     |
| Nervous system disorders                                                  |                         |                         |                           |                            |
| Nenvous ystem disordors,dny                                               | 2 (896)                 | 0 (0%)                  | 1 (496)                   | 0 (00)                     |
| Headacbe                                                                  | 1 (4%)                  | 0 (0%)                  | 0 (0%%)                   | 0 (0%6)                    |
| Peripheral sensory neuropathy                                             | 1 (4%)                  | (%0)0                   | 0 (0%6)                   | 0 (0%6)                    |
| Peripheral motor neuropathy                                               | 0 (0%)                  | 0(0%)                   | 1 (4%)                    | 0 (0%5)                    |
| Vaseular disorders                                                        |                         |                         |                           |                            |
| Vascular disorders,Ay                                                     | 2 (86)                  | 0(0%)                   | 0 (0%6)                   | 0 (0%6)                    |
| Flwshing                                                                  | 1 (4%)                  | 0 (0%)                  | 0 (0%6)                   | 0 (0%6)                    |
| Hypotension                                                               | 1(49)                   | (%0)0                   | 0 (0%%)                   | 0 (0%6)                    |
| Respiratory,thoracie and mediastinaldig orders                            |                         |                         |                           |                            |
| Respiraton, thoracic and mediastinal                                      | 1 (496)                 | (%0)0                   | 1 (4%)                    | 0 (0%6)                    |
| disordrs, day                                                             |                         |                         |                           |                            |
| Cough Dyspnoea                                                            | 1(4) (0)0               | 0 (0%) 0 (0%6)          | 0 (0%%) 1 (4%)            | 0 (06) 0 (0%6)             |

<div style=\"page-break-after: always\"></div>

| Skin and subcutaneous tissue disorders Skin andsubculancous fissue disorders   | 1 (4%)   | 2 (8%6)   | (960) 0   | 0 (0%)   |
|--------------------------------------------------------------------------------|----------|-----------|-----------|----------|
| Any                                                                            |          |           |           |          |
| Pnuritus                                                                       | 1 (4%)   | (%%0) 0   | 0 (0%6)   | 0 (0%)   |
| Alopecia                                                                       | 0 (0%)   | 1 (4%)    | 0 (0%6)   | 0 (0%)   |
| Rash maculo-papular                                                            | 0 (0%)   | 1 (4%)    | 0 (0%)    | 0 (0%)   |
| Urticania                                                                      | 0 (0%)   | 1 (4%)    | 0 (0%%)   | 0 (0%)   |
| Endocrine disorders                                                            |          |           |           |          |
| Endocrine disordersAy                                                          | 0 (0%)   | 1 (4%)    | 0 (0%%)   | 0 (0%)   |
| Hypothyroidism                                                                 | 0 (0%)   | 1 (4%)    | (960) 0   | 0 (0%)   |
| Immune system disorders                                                        |          |           |           |          |
| Inmwne 5ystem disorders,Any                                                    | 0 (0%)   | 0 (0%)    | 1 (4%)    | 0 (0%)   |
| Anaphylactie reaction                                                          | 0 (0%%)  | (%%0) 0   | 1 (49%6)  | 0 (0%)   |
| Infecdions and infestations                                                    |          |           |           |          |
| Infections and infestationsAny                                                 | 0 (0%)   | 0 (0%)    | 0 (0%%)   | 1 (4%)   |
| Infection                                                                      | (%0) 0   | (%%0) 0   | 0 (0%)    | 1 (4%)   |

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

In the pooled data, during vaccine treatment or within 30 days of the last vaccine therapy, a total of 17 (9.5%) patients experienced an SAE. Of these 17 patients, 9 were in the Lympreva with GM-CSF 100 µg/m 2  treatment group (7.8% of the treatment group) and 8 were in the KLH-KLH with GM-CSF 100 µg/m 2  control group (17.4% of the control group).

In study BV301, SAEs were reported in 8 patients in each study arm: in 11% of patients in the active arm and 17% in the control arm. A summary of Serious Adverse Events is reported on Table 25.

<div style=\"page-break-after: always\"></div>

Table 25: Summary of Serious Adverse Events Other than Death (Safety Set - Study BV301)

| MedDRAPreferredTerm/ Reported Term                                                 | Relationship to Study Drug/ GM-CSF    | Cycle/ Day/ Grade                     | Outcome/ActionTaken with Study Drug   |
|------------------------------------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Active (Dasiprotimut-T Biovest+GMCSF)                                              | Active (Dasiprotimut-T Biovest+GMCSF) | Active (Dasiprotimut-T Biovest+GMCSF) | Active (Dasiprotimut-T Biovest+GMCSF) |
| Vomiting / Vomiting                                                                | Unrelated/ NA                         | 6/NA/3                                | Resolved / No change                  |
| Anaphylactic reaction / Allergic reaction/ hypersensitivity (including drug fever) | Possible / Possible                   | 4/1/3                                 | Resolved/ Permanently stopped         |
| Non-cardiac chest pain / Chest pain                                                | Possible / Possible                   | 1/8/2                                 | Resolving / No change                 |
| Infection/Infection without neutropenia                                            | Unlikely / Unlikely                   | 4/16/2                                | Unresolved / No change                |
| Chest pain / Cardiovascular/general other (specify)                                | Unlikely / Unlikely                   | 3/1/2                                 | Resolved / No change                  |
| Anxiety / Mood alteration-anxiety, agitation                                       | Unrelated / Unrelated                 | 4/36/1                                | Resolved / No change                  |
| Urticaria / Urticaria (hives, welts, wheals)                                       | Probable / Probable                   | 4/7/3                                 | Resolved / No change                  |
| Cough / Cough                                                                      | Unlikely / Unlikely                   | 4/21/2                                | Resolved / No change                  |
| Infection/ Infection without neutropenia                                           | Unrelated / Unrelated                 | 2/9/2                                 | Resolved / No change                  |
| Bone pain/ Bone pain                                                               | Possible / Possible                   | 2/9/2                                 | Resolved / No change                  |
| Control (KLH-KLH+GM-CSF)                                                           | Control (KLH-KLH+GM-CSF)              | Control (KLH-KLH+GM-CSF)              | Control (KLH-KLH+GM-CSF)              |
| Herpes zoster / Site of shingles at L chest area - grade 2                         | Unlikely / Unlikely                   | 2/NA/2                                | Resolving / No change                 |
| Supraventricular tachycardia / supraventricular arrhythmia                         | NA / NA                               | 2/NA/3                                | NA / NA                               |
| Infection/Infection without neutropenia                                            | Unrelated/ Unrelated                  | 4/57/2                                | Resolved / No change                  |
| Blood cholesterolincreased/ Hypercholesterolemia                                   | Unrelated / Unrelated                 | 4/37/1                                | Unresolved / No change                |
| Dyspnoea / Dyspnea (shortness of breath)                                           | Probable / Probable                   | 4/1/3                                 | Resolved / No change                  |
| Compression fracture / musculoskeletal fracture                                    | Unlikely / Unlikely                   | 4/27/3                                | Resolved / No change                  |
| Cystitis interstitial/ Pain - other (specify)                                      | Unrelated/ Unrelated                  | 1/21/3                                | Resolved / No change                  |
| Sudden hearing loss /                                                              | Unrelated/                            | 2/16/2                                | Unresolved / No change                |
| Auditory/hearing (specify) Bone pain / Bone pain                                   | Unrelated Possible /                  | 2/9/2                                 | Unresolved / No change                |

treated.

CNS = central nervous system; CRF = case report form; F = female; GM-CSF = granulocyte macrophage colony-stimulating factor; KLH = keyhole limpet hemocyanin; M = male; NA = not assigned by site investigator

Additionally,  one  patient  experienced  the  following  Grade  4  TEAEs  in  Study  BV301: myocardial infarction (Cycle 2) and acute myeloid leukaemia (Cycle 6).

In  NCI  1033  study,  1  patient  had  SAEs  during  vaccine  therapy,  including  PTs  neutrophil  count decreased (Grade 4), WBC decreased (Grade 4) and dyspnoea (considered related to asthma); the neutropenia occurred 6 months after completed EPOCH-R therapy (6 courses, CR) and approximately 2 months after the first dose of vaccine, and lasted for at least 2 months before resolution during ongoing vaccine therapy at unchanged dosing.

Possible

<div style=\"page-break-after: always\"></div>

## Deaths

In the Summary Safety Population, no patients died while on study (i.e., at time of first dose or later) or within 30 days of the last dose of study drug.

## Laboratory findings

Clinical laboratory evaluations, vital signs and physical findings were not monitored during treatment in Lympreva clinical studies. Clinically significant abnormalities were to be reported as AEs.

## Safety in special populations

In the Summary Safety Population, Grade 3-4 events were reported in 10/17 patients (59%) aged ≥60 years and in 26/98 patients (27%) aged &lt;60 years.

Grade 3-4 events were experienced in 35% of female patients versus 25% of male patients.

## Safety related to drug-drug interactions and other interactions

N/A

## Discontinuation due to adverse events

In the Study BV301, 1 patient in the treatment arm discontinued permanently the therapy due to severe anaphylactic reaction (Cycle 4) and no one in the control arm. Additionally, 1 patient was noted in the CRF as discontinuing from the study due to \"toxicity/side effects\"; no specific TEAE was noted with an action taken of permanently discontinuation; however the patient did experience serious TEAEs. One patient in the active treatment group experienced 2 events (arthralgia and osteoporosis) that led to the study drug being temporarily stopped; similarly, 1 patient in the control treatment group had an event of muscle spasms which led to temporary interruption of the study drug.

In Study NCI 1033 and NCI T93-0164 no patients discontinued due to TEAEs.

## Post marketing experience

N/A

## 2.7.1. Discussion on clinical safety

Data on safety in the intended indication and dose was primarily derived from the randomised study BV301 with support from the uncontrolled studies NCI T93-0164 in FL and NCI 1033 in MCL. However, the pooling strategy (n=115 vs 46 controls) applied by the Applicant was  not considered acceptable without  justification,  mainly  due  to  the  inclusion  of  the  MCL  rituximab-exposed  group,  and  the assessment has primarily focused on the BV301 study in FL and the study1033 in MCL.

As  a  consequence  of  the  study  design  the  randomised  data  principally  allows  estimation  of Dasiprotimut-T toxicity upon combination with KLH and GM-CSF, but does not inform on KLH and GM-CSF toxicity over background morbidity. Thus, depiction of the causative toxicity profile of the active vaccination part of the combination is challenging.

Injection site reaction has been the most frequently reported adverse reaction, including induration, erythema, pruritus and pain. The other most commonly reported adverse reactions during treatment were oedema, flushing, chills, myalgia, arthralgia, fatigue, headache, chest pain, hypersensitivity, dizziness,  and  decreased  lymphocyte  count.  These  reactions  were  generally  mild  or  moderate, reversible and manageable. It should be noted that all these events are compatible with the known side effect profile of GM-CSF. Anticipated toxicities from GM-CSF administration are expected to be mild.  Potential  toxicities  include  fever,  chills,  myalgias,  arthralgias,  nausea,  vomiting,  diarrhea, dyspnea, tachycardia, arrhythmia, elevation of liver function tests, elevation of blood urea nitrogen (BUN)  and  creatinine.  However,  local  skin  reactions,  such  as  erythema  and  induration,  may  be

<div style=\"page-break-after: always\"></div>

observed and must be carefully noted.

Toxicity specifically related to the active component of the vaccine appears limited, but, when taking into account data obtained in both studies, may include a risk for hyperglycaemia and decreased white blood cells.

Immunocompromised patients,  such  as  patients  with  detectable  anti-HIV  antibodies,  hepatitis  B surface  antigen,  or  other  active  infectious  processes,  were  excluded  from  clinical  trials  due  to potential  interferences  with  the  development  of  an  immune  response  to  the  tumour  antigen. Lympreva has not been evaluated in HIV positive patients, nor in patients on antiretroviral therapy. Lympreva has not been evaluated in patients with a history of hepatitis B exposure

Serious adverse reactions associated with therapy with Lympreva with GM-CSF include anaphylactic reaction, urticaria, neutrophil count decreased, white blood cell count decreased, bone pain, cough, and dyspnoea. Except for the anaphylactic reaction which occurred after the fourth immunization and resulted in treatment discontinuation, these serious reactions were reversible and did not affect the course of therapy.

In  the  controlled  trial,  1.7%  of  patients  discontinued  treatment  with  Lympreva  due  to  adverse reactions.

Although grade ≥3 events were reported in 30% of patients in the pooled active vaccination group, and SAEs occurred, discontinuation rate due to AE was low (1 or 2 patients in BV301 and none in NCI 1033) and no patient died due to AE. Therefore, the toxicity associated with Lympreva was generally considered clinically manageable, but the report of one patient with an injection-related ulceration of &gt;10 cm is worrisome.

Leukopenia  was  noted  in  patients  under  active  vaccine  treatment,  including  neutropenia  and lymphocytopenia.  While  confounded  by  previous  exposure  to  rituximab  in  the  MCL  study,  these cytopenias were also reported numerically more frequent in the active arm vs the control arm of study BV301.

There was one case of leukoencephalopathy in the active arm, but no conclusions can be drawn based on this single event. Nonetheless, the Applicant had addressed this issue in the proposed RMP.

In BV301, 8 of the 10 patients reporting secondary malignancy were on active treatment. No pattern in terms of histology or temporal trend was noted. An increased incidence of secondary malignancies is expected in the present study population. However, as the incidence was numerically distinctly higher in the active treatment arm, secondary malignancies are included as a potential risk in the RMP.

In  terms  of  external  validity  of  the  safety  data,  the  general  median  age  at  diagnosis  in  FL  of approximately 60 years is not reflected in the study populations of BV301 or NCI T93-0164, in which age at time of study enrolment was ≥60 years in only 16% and 8%, respectively. Further, the majority of patients presented with low risk disease and in the pooled population (n=115) only 12 patients had an ECOG PS of 1 while all others with data available had an ECOG PS of 0. Although low patient numbers exclude a reasonably robust evaluation of safety by age, it is noted that grade 3-4 events occurred numerically more common patients ≥60 years of age (10/17 patients (59%) aged ≥60 years vs in 26/98 patients (27%) aged &lt;60 years). Therefore, the characterisation of the toxicity profile associated with active vaccination specifically in the general main target FL population cannot be considered robust.

Another issue relates to the capture of data on clinical laboratory evaluations and vital signs and physical findings. Such data was not monitored at baseline and during treatment in the clinical studies except for clinically significant abnormalities to be reported as AEs. This makes evaluation of safety issues difficult. Safety in patients with renal or hepatic impairment, or of non-white ethnicity, remains to be determined.

<div style=\"page-break-after: always\"></div>

Long-term safety after active immunotherapy is lacking.

Lympreva has a minor influence on the ability to drive and use machines.

There have been no reports of overdose with Lympreva. Lympreva has been administered in clinical trials only in the currently recommended dose.

## 2.7.2. Conclusions on the clinical safety

The toxicity of active vaccination treatment seems to be dominated by the GM-CSF component but may  also  include a risk for leukopenia, including  neutropenia  and  lymphocytopenia,  and hyperglycaemia. Although deemed generally clinically manageable, with low rates of discontinuations due to AE, one patient was reported with an injection-related ulceration of &gt;10 cm and there was a numerical increase in secondary malignancies in the active treatment arm. There was one case of leukoencephalopathy in the active arm, but no conclusions can be drawn based on this single event. Nonetheless, the Applicant had addressed this issue in the proposed RMP. Issues challenging the internal and external validity of the database have been identified.

## 2.8. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

## 2.9. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 1.2 could be acceptable if the applicant implements the changes to the RMP as described in the PRAC endorsed PRAC Rapporteur assessment report.

The CHMP, having considered the data submitted in the application was of the opinion that it was not appropriate to consider risk minimisation activities at this time.

## 2.10. Product information

The CHMP, having considered the data submitted in the application was of the opinion that it was not appropriate to agree on the Product Information at this time.

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Labelling exemptions

A request of translation exemption of the labelling as per Art.63.3 of Directive 2001/83/EC has been submitted by the applicant and has been found acceptable for the packaging part only by the QRD

<div style=\"page-break-after: always\"></div>

Group for the following reasons:

The Group agreed an English only packaging based on the applicant's justification; however, the PL should be in the national language.

The labelling subject to translation exemption as per the QRD Group decision above will however be translated in all languages in the Annexes published with the EPAR on EMA website, but the printed materials will only be translated in the language(s) as agreed by the QRD Group.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

No  significant  difference  in  DFS  was  shown  between  subjects  randomised  to  active  vs.  control vaccination  (log-rank  p-value  0.295),  and  the  same  was  observed  for  all  subgroups  analysed. Therefore, efficacy for Lympreva has not been demonstrated in the pivotal study.

## Uncertainty in the knowledge about the beneficial effects

Major concerns have been raised on the design of the trial and more specifically on the definition of the  population  used  for  the  primary  analysis,  which  may  introduce  bias.  The  difference  in  DFS between  the  two  arms  is  limited  to  the  subpopulation  that  underwent  vaccination  and  it  was calculated by including only patients who achieved CR/CRu after induction with PACE and underwent randomisation between active and control vaccination.

Notwithstanding the fact that efficacy has not been established, the intensive induction regimen (PACE) used to induce CR from FL before vaccination is not standard of care. There are no data to show clinical efficacy of Lympreva with induction regimens used in current clinical practice.  In view of the important differences between the PACE regimen and the current regimens that include CD20 antibodies, it is not possible to generalise the effect observed between regimens.

## Risks

## Unfavourable effects

Injection site reaction has been the most frequently reported adverse reaction, including induration, erythema, pruritus and pain. The other most commonly reported adverse reactions during treatment were oedema, flushing, chills, myalgia, arthralgia, fatigue, headache, chest pain, hypersensitivity, dizziness,  and  decreased  lymphocyte  count.  These  reactions  were  generally  mild  or  moderate, reversible and manageable. It should be noted that all these events are compatible with the known side effect profile of GM-CSF. Toxicity specifically related to the active component of the vaccine appears limited, but, when taking into account data obtained in both studies, may include a risk for hyperglycaemia and decreased white blood cells.

Serious adverse reactions associated with therapy with Lympreva with GM-CSF include anaphylactic reaction, urticaria, neutrophil count decreased, white blood cell count decreased, bone pain, cough, and dyspnoea. Except for the anaphylactic reaction which occurred after the fourth immunization and resulted in treatment discontinuation, these serious reactions were reversible and did not affect the course of therapy. One patient experienced an injection-related ulceration of &gt;10 cm.

In  the  controlled  trial,  1.7%  of  patients  discontinued  treatment  with  Lympreva  due  to  adverse reactions.

<div style=\"page-break-after: always\"></div>

## Uncertainty in the knowledge about the unfavourable effects

In BV301, 8 of the 10 patients reporting secondary malignancy were on active treatment. No pattern in  terms  of  histology  or  temporal  trend  was  noted.  However,  as  the  incidence  was  numerically distinctly higher in the active treatment arm, secondary malignancies were included as a potential risk in the RMP.

With only 16% and 8% of patients ≥60 years of age in study BV301 and NCI T93-0164, respectively, and  only  12/115  patients  in  the  pooled  population  with  ECOG  PS  1  (none  with  PS  2),  the characterisation of the toxicity profile associated with active vaccination specifically in the general main target FL population, with a median age at diagnosis of approximately 60 years, cannot be considered robust. Thus, the external validity of the safety data might be questionable; especially as grade 3-4 events were numerically more common in patients ≥60 years of age.

However, given the assumption that immune-related reactions directly  associated  with  the  drug hardly can be expected to increase with age, it could have been considered acceptable to collect safety data in an older population as a post-approval commitment as part of the RMP.

There was one case of leukoencephalopathy in the active arm, but no conclusions can be drawn based on this single event. Nonetheless, the Applicant had addressed this issue in the proposed RMP.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

DFS is an accepted outcome measure of adjuvant therapy in patients with FL in remission after induction therapy. A favourable effect, however, has not been demonstrated. In addition, there are no data to show clinical efficacy of Lympreva with induction regimens used in current clinical practice.

Although grade ≥3 events were reported in 30% of patients in the pooled Lympreva group, and SAEs occurred, discontinuation rate due to AE was low. Therefore, the toxicity associated with Lympreva is generally considered clinically manageable.

## Benefit-risk balance

## Discussion on the benefit-risk balance

A number of the Major Objections related to the quality of the product remain. Although much work had been done by the Applicant, there are still outstanding issues that are critical for this type of finished  product  and  its  manufacturing  process.  There  are  limited  possibilities  for  control  of  the finished product due to the properties of the active substance, the limited batch size (about 20-30 vials) and that each batch is patient specific with the autologous immunoglobulin component. In view of these circumstances it is crucial that the manufacturing process is validated and capable to deliver a consistent product for which safety can be ensured with validated aseptic process. This was not demonstrated.

In  the  absence  of  established  clinical  efficacy  and  quality,  the  benefit-risk  balance  cannot  be considered positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy for Lympreva in the treatment of patients  with  follicular  non-Hodgkin's  lymphoma  (FL)  as  consolidation  therapy  after  achieving complete remission  with  induction  therapy  and  is  co-administered  with  Granulocyte  Macrophage Colony-Stimulating Factor (GM-CSF) the CHMP considers by consensus that the quality and efficacy of    the  above  mentioned  medicinal  product  is  not  sufficiently  demonstrated,  and,  therefore recommends the refusal of the granting of the Marketing Authorisation for the above mentioned medicinal product. The CHMP considers that:

- The quality of the critical intermediate KLH was insufficiently guaranteed. The CTD section dealing with the critical intermediate KLH is deemed deficient and incomplete. A major issue was the lack of process validation.
- The manufacturing process lacked full process validation and sufficient control of bioburden.
- Viral clearance and viral inactivation data for the IgM and IgG processes was insufficient and therefore, a final conclusion on viral safety cannot be drawn.
- Comparability between material from the manufacturing process used for clinical batches and material from the commercial manufacturing process had not been demonstrated as studies were incomplete.
- Process related impurities are insufficiently controlled as specifications with associated actual limits were not defined and analytical methods for their determination were not validated.
- Characterisation  data  are  incomplete  and  several  characterisation  tests  had  not  been qualified.
- Critical Quality Attributes should be within specifications, despite large yield differences due to variability between batches, this has not been demonstrated.
- Stability:  Stability  for  bulk  IgM  and  IgG  during  shelf  life  had  not  been  demonstrated.  In addition, stability for the medicinal product manufactured with the commercial process had not been demonstrated.
- Compatibility of the product with regards to the instructions for use and handling in the proposed Summary of product characteristics (co-administration of Lympreva and GM-CSF in one syringe; in use shelf life) had not been demonstrated.
- There  are  significant  and  unresolved  concerns  regarding  the  design  of  the  pivotal  study BV301. The analyses of the efficacy results did not sufficiently demonstrate the efficacy of the product and do not support of a marketing authorisation.
- The clinical efficacy of Lympreva in FL after induction with anti-CD20 antibodies, the mainstay of current clinical practice, has not been demonstrated.

<div style=\"page-break-after: always\"></div>

## REFERENCES

1. Campbell, M.J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J.B., Levy, S., Levy, R., 1987. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumour-derived immunoglobulin M and its molecular subunits. Journal of immunology 139, 2825-2833.
2. Campbell, M.J., Esserman, L., Levy, R., 1988. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. Journal of immunology 141, 3227-3233.
3. Campbell, M.J., Esserman, L., Byars, N.E., Allison, A.C., Levy, R., 1990. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumour immunity. Journal of immunology 145, 1029-1036.
4. George, A.J., Folkard, S.G., Hamblin, T.J., Stevenson, F.K., 1988. Idiotypic vaccination as a treatment for a B cell lymphoma. Journal of immunology 141, 2168-2174.
5. Goodlad JR, MacPherson S, Jackson R, Batstone P, White J., 2004. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology 44, 268-276.
6. Heyfets, A., Haimovich, J., Hollander, N., 2002. Determination of idiotype-specific T cells in idiotype-vaccinated mice. Immunology letters 80, 207-213.
7. Kaminski, M.S., Kitamura, K., Maloney, D.G., Levy, R., 1987. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumour immunity by free idiotype protein. Journal of immunology 138, 1289-1296.
8. Kwak, L.W., Campbell, M.J., Zelenetz, A.D., Levy, R., 1990. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumour-derived idiotypic immunoglobulin. Blood 76, 2411-2417.
9. Kwak, L.W., Young, H.A., Pennington, R.W., Weeks, S.D., 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proceedings of the National Academy of Sciences of the United States of America 93, 10972-10977.
10. F. Morschhauser et al. 'Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.' In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26.32 (2008), pp. 5156-64.
11. A. Z. Rohatiner and T. A. Lister. 'The clinical course of follicular lymphoma.' In: Best practice &amp; research. Clinical haematology 18.1 (2005), pp. 1-10.
12. Mathias J. Rummel et al. 'Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.' eng. In: Lancet (Feb. 2013).
13. G. A. Salles et al. 'Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.' eng. In: Lancet 377.9759 (Jan. 2011), pp. 42-51.
14. Sugai, S., Palmer, D.W., Talal, N., Witz, I.P., 1974. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. The Journal of experimental medicine 140, 1547-1558.